New medicines.
Clearer context.

Reference reviewed 17 September 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Reference reviewed 3 October 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Reference reviewed 15 September 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Reference reviewed 15 September 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Reference reviewed 15 September 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Reference reviewed 30 September 2026 · Update awaiting review

This reference needs review. The dated information below is the last reviewed reference; check the linked authority for the latest position.

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Daily injectable GLP-1 treatment. The UK product information includes adult weight management with dietary changes and physical activity.

• Saxenda: UK product informationUK product information · Published/updated: 27 November 2025 · Source review: 6 October 2026 · Source review required
• NICE TA664: liraglutide recommendationsNICE guidance · Published/updated: 9 December 2020 · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Oral combination authorised for adult weight management within specified BMI and comorbidity criteria.

• Mysimba: UK product informationUK product information · Published/updated: 28 September 2026 · Source review: 6 October 2026 · Source review required
• NICE TA494: naltrexone–bupropion recommendationsNICE guidance · Published/updated: 12 December 2017 · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A specialist medicine whose UK indications include specified genetic forms and acquired hypothalamic obesity. This is not a general obesity option.

• Imcivree: UK product informationUK product information · Published/updated: 18 August 2026 · Source review: 6 October 2026 · Source review required
• NICE HST21: POMC and LEPR deficiencyNICE guidance · Published/updated: 6 July 2022 · Source review: 6 October 2026 · Source review required
• NICE HST31: Bardet–Biedl syndromeNICE guidance · Published/updated: 22 May 2024 · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Novo reported REIMAGINE 5 and REDEFINE 9 results on 21 September 2026 for cagrilintide plus semaglutide. A US application is not a UK approval.

• Novo Nordisk: REIMAGINE 5 and REDEFINE 9Original sponsor statement; not regulatory approval · Published/updated: 21 September 2026 · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Novo’s annual-report narrative describes cagrilintide being developed on its own, separately from CagriSema.

• Novo Nordisk annual report: innovation and pipelineOriginal sponsor statement; not regulatory approval · Published/updated: Not stated by the source · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Novo describes a single molecule targeting GLP-1 and amylin receptors. Its annual report describes weight-management Phase 3 development in early 2026. A sponsor-submitted Phase 1 record, first posted 2 October 2026, plans to assess tolerability in an estimated 60 adults switching from maintenance semaglutide to subcutaneous zenagamtide. A separate sponsor-submitted Phase 1 record, updated 1 October 2026, studies once-weekly subcutaneous NNC0487-0111/amycretin against placebo or a low-energy diet after weight loss, focusing on sleeping and 24-hour energy expenditure in 120 estimated participants. Novo Nordisk's sponsor-submitted AMBIENCE record, first posted 6 October 2026, plans a placebo-controlled Phase 3 cardiovascular-outcomes study of once-weekly subcutaneous zenagamtide in an estimated 8,500 adults with established atherosclerotic cardiovascular disease and overweight or obesity. The primary endpoint is time to first four-point major adverse cardiovascular event, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or heart-failure hospitalisation or urgent visit. A separate sponsor-submitted Phase 1 record, first posted 9 October 2026, plans to assess tolerability when an estimated 60 adults with overweight or obesity, with or without type 2 diabetes, switch from maintenance tirzepatide to subcutaneous zenagamtide.

• Novo Nordisk annual report: innovation and pipelineOriginal sponsor statement; not regulatory approval · Published/updated: Not stated by the source · Source review: 6 October 2026 · Source review required
• ClinicalTrials.gov NCT07855133: switching from semaglutide to zenagamtideTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 2 October 2026 · Updated 16 October 2026Start 5 October 2026 (actual) · Primary completion 6 September 2028 (estimated) · Completion 6 September 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 18 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07757087: subcutaneous amycretin and energy expenditureTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 11 August 2026 · Updated 1 October 2026Start 3 August 2026 (actual) · Primary completion 18 September 2028 (estimated) · Completion 18 September 2028 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07861100: AMBIENCE zenagamtide cardiovascular-outcomes studyTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 6 October 2026 · Updated 6 October 2026Start 26 October 2026 (estimated) · Primary completion 16 September 2030 (estimated) · Completion 16 September 2030 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07868354: tirzepatide-to-zenagamtide switch-tolerability studyTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 9 October 2026 · Updated 9 October 2026Start 8 October 2026 (estimated) · Primary completion 7 September 2028 (estimated) · Completion 7 September 2028 (estimated)Medical evidence summary reviewed 10 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Amgen’s Q2 2026 update reports ongoing MARITIME weight-management studies, with separate studies for associated conditions. Three sponsor-submitted records updated on 5 October 2026 identify recruiting Phase 3 research: MARITIME-1-EXTENSION in adults with obesity or overweight, MARITIME-2-EXTENSION in adults with obesity or overweight and type 2 diabetes, and a separate cardiovascular-outcomes study in adults with atherosclerotic cardiovascular disease and obesity or overweight. The two extension records report actual July 2026 starts; the cardiovascular record reports an actual July 2025 start. A separate Phase 3 record updated on 6 October 2026 studies maridebart cafraglutide in 250 estimated adults with obstructive sleep apnoea using positive-airway-pressure therapy and overweight or obesity. It is active, not recruiting after an actual 19 December 2025 start. A separate sponsor-submitted Phase 3 MARITIME-T2D-3 record, first posted 8 October 2026, plans to compare once-monthly maridebart cafraglutide with once-weekly semaglutide as add-on therapy in 1,300 estimated adults with type 2 diabetes. Its primary endpoint is HbA1c non-inferiority at week 68; body-weight measures are secondary outcomes.

• Amgen: Q2 2026 pipeline updateOriginal sponsor statement; not regulatory approval · Published/updated: Not stated by the source · Source review: 6 October 2026 · Source review required
• ClinicalTrials.gov NCT07684235: MARITIME-1-EXTENSIONTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 6 July 2026 · Updated 5 October 2026Start 23 July 2026 (actual) · Primary completion 26 December 2027 (estimated) · Completion 19 March 2028 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07684144: MARITIME-2-EXTENSIONTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 6 July 2026 · Updated 5 October 2026Start 29 July 2026 (actual) · Primary completion 26 December 2027 (estimated) · Completion 19 March 2028 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07037433: MariTide cardiovascular-outcomes studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 25 June 2025 · Updated 8 October 2026Start 25 July 2025 (actual) · Primary completion 30 June 2028 (estimated) · Completion 29 September 2030 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07225686: MariTide in obstructive sleep apnoea on PAP therapyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 10 November 2025 · Updated 6 October 2026Start 19 December 2025 (actual) · Primary completion 20 August 2027 (estimated) · Completion 21 July 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07866066: MARITIME-T2D-3 MariTide versus semaglutideTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 8 October 2026 · Updated 8 October 2026Start 2 November 2026 (estimated) · Primary completion 4 September 2028 (estimated) · Completion 4 December 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Zealand reported SYNCHRONIZE-2 results on 1 October 2026: in adults with obesity/overweight and type 2 diabetes, mean weight loss reached 13.1% versus 3.1% with placebo at 76 weeks under the efficacy estimand. Gastrointestinal adverse events led to discontinuation in 18% versus 1.2%. A sponsor-submitted Phase 3 SYNCHRONIZE-HERA record, first posted 30 September 2026, studies survodutide in an estimated 600 women going through or after menopause. A sponsor-submitted Phase 3b SYNCHRONIZE-START record plans a pragmatic initiation study in an estimated 350 adults, including people switching from semaglutide or tirzepatide to survodutide. The peer-reviewed SYNCHRONIZE-2 abstract reports the treatment-regimen estimand at week 76: mean body-weight change was -9.8% with 6.0 mg, -8.2% with 3.6 mg and -3.9% with placebo; the corresponding HbA1c changes were -0.8, -0.9 and -0.2 percentage points. Separately, NCT07754461 records a recruiting 56-week Phase 3 study of survodutide versus placebo for glycaemic control in people with type 2 diabetes, after an actual 24 August 2026 start. Its estimated enrolment is 600. Boehringer Ingelheim's 5 October 2026 Japanese announcement reports SYNCHRONIZE-JP results after 76 weeks in 274 participants. It reports mean body-weight changes of -12.5% with 3.6 mg and -13.1% with 6.0 mg versus -1.6% with placebo. In a separate MRI-assessed subset it also reports reductions in visceral and liver fat. The sponsor-submitted NCT06176365 record is completed after an actual 16 January 2024 start and 3 December 2025 completion, but has no registry-posted results.

• Zealand: survodutide Phase III resultsOriginal sponsor statement; not regulatory approval · Published/updated: 7 June 2026 · Source review: 9 October 2026 · Source review required
• survodutide-synchronize2-20261001Original source — see findings and limitations · Published 1 October 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored.
• survodutide-synchronize2-registryTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 4 October 2023 · Updated 6 August 2026Start 27 November 2023 (actual) · Primary completion 12 December 2025 (actual) · Completion 1 April 2026 (actual)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07850050: SYNCHRONIZE-HERATrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 30 September 2026 · Updated 30 September 2026Start 31 October 2026 (estimated) · Primary completion 26 July 2028 (estimated) · Completion 26 July 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07855900: SYNCHRONIZE-STARTTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 2 October 2026 · Updated 2 October 2026Start 7 November 2026 (estimated) · Primary completion 25 June 2028 (estimated) · Completion 25 June 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Survodutide Once Weekly in Adults with Obesity and Type 2 DiabetesPublished research — see study design · Published 1 October 2026 · Reviewed 4 October 2026 · Peer-reviewed PubMed abstract read for design, population, treatment-regimen estimand, body-weight and HbA1c results, adverse-event context and funding. The full NEJM article returned HTTP 403 and was not reviewed; this evidence URL is not automatically content-monitored.
• ClinicalTrials.gov NCT07754461: survodutide type 2 diabetes Phase 3 studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 10 August 2026 · Updated 30 September 2026Start 24 August 2026 (actual) · Primary completion 17 January 2028 (estimated) · Completion 1 May 2028 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Boehringer Ingelheim Japan: SYNCHRONIZE-JP Phase III resultsOriginal source — see findings and limitations · Published 5 October 2026 · Reviewed 6 October 2026 · Original sponsor announcement read for the Japanese Phase III population, completed 76-week comparison, reported group-level weight and MRI-subset findings and gastrointestinal adverse-event summary. Direct retrieval returned HTTP 403, so this page is not assigned an automatic green baseline.
• ClinicalTrials.gov NCT06176365: SYNCHRONIZE-JPTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 19 December 2023 · Updated 30 April 2026Start 16 January 2024 (actual) · Primary completion 3 December 2025 (actual) · Completion 3 December 2025 (actual)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Viking's sponsor-submitted SUNRISE 1 and SUNRISE 2 records, both first posted 9 October 2026, describe separate 68-week oral VK2735 Phase 3 studies in adults without and with type 2 diabetes. Each plans 560 participants and remains not yet recruiting. Separately, Viking reported Part 1 maintenance observations in approximately 180 adults and says Part 2 has now started in approximately 195 adults, testing oral and subcutaneous maintenance after weekly subcutaneous induction. Its injectable VANQUISH Phase 3 studies are ongoing.

• Viking: Q2 2026 programme updateOriginal sponsor statement; not regulatory approval · Published/updated: 29 July 2026 · Source review: 6 October 2026 · Source review required
• Viking: VK2735 maintenance-study topline resultsOriginal sponsor announcement; topline results, not regulatory approval · Published/updated: 22 September 2026 · Source review: 11 October 2026 · Source review required
• Viking: VK2735 oral-maintenance Part 2 initiationOriginal sponsor announcement; trial initiation, not regulatory approval · Published/updated: 6 October 2026 · Source review: 6 October 2026 · Source review required
• Viking: VK2735 maintenance-study topline resultsOriginal source — see findings and limitations · Published 22 September 2026 · Reviewed 4 October 2026 · Complete original sponsor announcement reviewed for study population, induction and maintenance periods, randomized regimens, topline-result status and planned oral-maintenance work.
• Viking: VK2735 oral-maintenance Part 2 initiationOriginal source — see findings and limitations · Published 6 October 2026 · Reviewed 6 October 2026 · Complete original sponsor announcement reviewed for initiation, study population, induction and maintenance regimens, objectives, exploratory endpoint and expected-results timing. The sponsor's isolated VK2375 typo is not adopted as a separate programme.
• ClinicalTrials.gov NCT07868835: oral VK2735 SUNRISE 1 Phase 3Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 9 October 2026 · Updated 9 October 2026Start 15 October 2026 (estimated) · Primary completion 1 July 2028 (estimated) · Completion 1 August 2028 (estimated)Medical evidence summary reviewed 10 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07868939: oral VK2735 SUNRISE 2 Phase 3Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 9 October 2026 · Updated 9 October 2026Start 16 October 2026 (estimated) · Primary completion 1 October 2028 (estimated) · Completion 1 December 2028 (estimated)Medical evidence summary reviewed 10 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 8 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Zealand announced ZUPREME-2 diabetes Phase 2 topline results on 7 October 2026, reporting 7.4–9.2% mean weight reduction at week 28 using the efficacy estimand versus 2.0% with placebo. These are sponsor-reported findings pending full results. The completed NCT06926842 registry has no posted results and records 221 actual participants, whereas the sponsor reports 220. ZUPREME-3, ZUPREME-4 and ZUPREME-5 are now recruiting. ZUPREME-3 and -5 record actual 30 September starts; ZUPREME-4 retains an estimated 30 September start. The populations are respectively without type 2 diabetes, with type 2 diabetes, and with established cardiovascular disease.

• Zealand Pharma: ZUPREME-1 publication and Phase 3 programme statusOriginal sponsor release distributed by GlobeNewswire · Published/updated: 29 September 2026 · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov NCT06926842: completed ZUPREME-2 diabetes Phase 2 studyTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 15 April 2025 · Updated 9 September 2026Start 22 April 2025 (actual) · Primary completion 13 August 2026 (actual) · Completion 13 August 2026 (actual)Medical evidence summary reviewed 8 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07843472: ZUPREME-5 with established cardiovascular diseaseTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 28 September 2026 · Updated 7 October 2026Start 30 September 2026 (actual) · Primary completion 28 July 2030 (estimated) · Completion 6 October 2030 (estimated)Medical evidence summary reviewed 8 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07843485: ZUPREME-4 with type 2 diabetesTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 28 September 2026 · Updated 7 October 2026Start 30 September 2026 (estimated) · Primary completion 20 October 2028 (estimated) · Completion 19 January 2029 (estimated)Medical evidence summary reviewed 8 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07843498: ZUPREME-3 without type 2 diabetesTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 28 September 2026 · Updated 7 October 2026Start 30 September 2026 (actual) · Primary completion 21 December 2028 (estimated) · Completion 22 March 2029 (estimated)Medical evidence summary reviewed 8 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Zealand: 7 October 2026 ZUPREME-2 topline announcementOriginal source — see findings and limitations · Published 7 October 2026 · Reviewed 8 October 2026 · Complete original sponsor announcement read; topline findings only. Outside automatic content monitoring; no verified monitor fingerprint.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Lilly's 30 September 2026 release reports a completed 48-week Phase 2b study of eloralintide plus tirzepatide in 367 adults with obesity or overweight and type 2 diabetes. Eloralintide monotherapy Phase 3 trials are ongoing; EloraTZP co-formulation Phase 3 trials were planned for Q4 2026 and are not treated as started.

• Lilly: EloraTZP Phase 2b resultsOriginal sponsor results announcement; not regulatory approval · Published/updated: 30 September 2026 · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov record NCT06603571Original source — see findings and limitations · Published 29 September 2026 · Reviewed 1 October 2026 · Sponsor-submitted registry evidence for completed Phase 2 status, actual dates and enrolment; not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Structure’s 8 September update confirms Phase 3 ACCOMPLISH studies of its oral GLP-1 candidate. Earlier Phase 2 reports no longer describe the full development stage. The sponsor-submitted NCT07654374 record now shows ACCOMPLISH-2 recruiting after an actual 17 July 2026 start. The Phase 3 study evaluates oral once-daily aleniglipron in adults with obesity or overweight and type 2 diabetes, with 1,100 estimated participants and a week-76 body-weight endpoint.

• Structure: aleniglipron and oral amylin updateOriginal sponsor statement; not regulatory approval · Published/updated: 8 September 2026 · Source review: 6 October 2026 · Source review required
• ClinicalTrials.gov NCT07654374: ACCOMPLISH-2Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 17 June 2026 · Updated 11 September 2026Start 17 July 2026 (actual) · Primary completion 1 September 2028 (estimated) · Completion 1 November 2028 (estimated)Medical evidence summary reviewed 11 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Structure describes an investigational oral small-molecule amylin/calcitonin receptor agonist. Early clinical development is distinct from late-stage treatment evidence.

• Structure: aleniglipron and oral amylin updateOriginal sponsor statement; not regulatory approval · Published/updated: 8 September 2026 · Source review: 6 October 2026 · Source review required

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Pfizer's 3 February update reports VESPER-4 initiation. Pfizer's later participant page describes the once-monthly VESPER-6 study, and the sponsor-submitted registry record names the medicine berobenatide (PF-08653944), lists the study as recruiting and records an actual 10 June 2026 start.

• Pfizer: VESPER development updatePfizer original release; exact official investor-hosted PDF bytes are automatically monitored, not regulatory approval · Published/updated: 3 February 2026 · Source review: 9 October 2026 · Source review required
• Pfizer VESPER-6 participant informationOriginal sponsor trial-participant information; not regulatory approval · Published/updated: Not stated by the source · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov NCT07595549 (VESPER-6)Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 19 May 2026 · Updated 28 September 2026Start 10 June 2026 (actual) · Primary completion 4 May 2028 (estimated) · Completion 21 June 2028 (estimated)Medical evidence summary reviewed 30 September 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 7 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Roche reported CT388-104 results on 22 September 2026 in adults with type 2 diabetes and overweight or obesity. ENITH-1/2 weight-management trials are ongoing; additional diabetes and cardiovascular Phase III studies are planned for the first half of 2027. The sponsor-submitted NCT06525935 record now describes the 48-week Phase 2 obesity study as completed after an actual 16 August 2024 start and 8 December 2025 completion, with 469 actual participants. A separate enicepatide Phase 2 study in 447 actual participants with type 2 diabetes and overweight or obesity was updated on 6 October 2026. The record reports an actual 21 November 2024 start, actual 29 May 2026 primary completion and actual 30 September 2026 study completion. The exact ENITH-1 and ENITH-2 Phase 3 records are recruiting after actual 16 and 23 March 2026 starts. ENITH-1 estimates 2,000 participants without type 2 diabetes and ENITH-2 estimates 1,600 participants with type 2 diabetes; both retain estimated 2028 completion dates.

• Roche: ADA 2026 obesity programme announcementOriginal sponsor statement; not regulatory approval · Published/updated: 1 June 2026 · Source review: 6 October 2026 · Source review required
• Enicepatide CT388-104 Phase II resultssponsor announcement · Published/updated: 22 September 2026 · Source review: 9 October 2026 · Source review required
• Roche Q1 2026 presentation, page 33Original source — see findings and limitations · Published 23 April 2026 · Reviewed 29 September 2026 · PDF read for trial-stage evidence; not automatically content-monitored.
• ClinicalTrials.gov NCT06525935: enicepatide Phase 2 obesity studyTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 29 July 2024 · Updated 5 October 2026Start 16 August 2024 (actual) · Primary completion 8 December 2025 (actual) · Completion 8 December 2025 (actual)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06628362: completed enicepatide Phase 2 diabetes studyTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 8 October 2024 · Updated 6 October 2026Start 21 November 2024 (actual) · Primary completion 29 May 2026 (actual) · Completion 30 September 2026 (actual)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07351045: ENITH-1 without type 2 diabetesTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 20 January 2026 · Updated 14 September 2026Start 16 March 2026 (actual) · Primary completion 24 July 2028 (estimated) · Completion 28 August 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07351058: ENITH-2 with type 2 diabetesTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 20 January 2026 · Updated 14 September 2026Start 23 March 2026 (actual) · Primary completion 7 August 2028 (estimated) · Completion 7 August 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Roche for Patients: ENITH-1Original source — see findings and limitations · Published Not stated by the source · Reviewed 7 October 2026 · Official sponsor study page reviewed for programme identity and study population; publication and update dates were not verified and the page is not automatically monitored.
• Roche for Patients: ENITH-2Original source — see findings and limitations · Published Not stated by the source · Reviewed 7 October 2026 · Official sponsor study page reviewed for programme identity and study population; publication and update dates were not verified and the page is not automatically monitored.

Evidence summary reviewed 29 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Pfizer announced discontinuation on 14 April 2025. It should not remain on a list of advancing treatment candidates.

• Pfizer: danuglipron discontinuedPfizer original release; exact official investor-hosted PDF bytes are automatically monitored, not regulatory approval · Published/updated: 14 April 2025 · Source review: 9 October 2026 · Source review required

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Zealand’s 13 November 2025 financial update records development paused as a portfolio decision. This dated announcement does not establish subsequent resumption; paused is not permanently discontinued.

• Zealand: first nine months of 2025; dapiglutide pausedOriginal sponsor statement; not regulatory approval · Published/updated: 13 November 2025 · Source review: 9 October 2026 · Source review required

Evidence summary reviewed 7 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Amgen’s Q2 2026 update says future development will stop while the existing Phase 1 study follows enrolled participants through completion. The sponsor-submitted Phase 1 record was updated on 6 October 2026 and now reports completed status after an actual 16 September 2026 completion, with 82 actual participants.

• Amgen: Q2 2026 pipeline updateOriginal sponsor statement; not regulatory approval · Published/updated: Not stated by the source · Source review: 6 October 2026 · Source review required
• ClinicalTrials.gov NCT06585462: completed AMG 513 Phase 1 studyTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 5 September 2024 · Updated 6 October 2026Start 9 September 2024 (actual) · Primary completion 16 September 2026 (actual) · Completion 16 September 2026 (actual)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: AstraZeneca reported VISTA and SOLSTICE results and advancement into EMBOLD obesity and ELUMINATE diabetes development. This does not verify initiation of every planned trial.

• Elecoglipron Phase IIb results and Phase III plansAstraZeneca original release distributed by Cision; not regulatory approval · Published/updated: 8 June 2026 · Source review: 9 October 2026 · Source review required

Evidence summary reviewed 7 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Kailera's 30 September 2026 announcement says enrolment is complete across the three global Phase 3 KaiNETIC injection trials: approximately 2,500 adults in KaiNETIC-1, 1,200 in KaiNETIC-2 and 1,200 in KaiNETIC-3. Topline data are expected in mid-2028; this is a planned date, not a completed result. Kailera reported a separate 51-participant Phase 1 injection-site study. This does not change the global Phase 3 stage or prove results from the fully enrolled KaiNETIC programme. Two separate Chinese sponsor-submitted Phase 3 records add specialist and comparator contexts: NCT07285902 is active, not recruiting after an actual 25 December 2025 start and compares HRS9531 injection with semaglutide in 572 actual participants; NCT07709910 studies ribupatide in people with obesity and knee osteoarthritis but remains not yet recruiting with an estimated July 2026 start and 382 estimated participants. Broader registry discovery found two recruiting Chinese Phase 3 obstructive-sleep-apnoea studies (NCT06974851 and PAP-treated NCT06994650), a recruiting 9,262-participant Phase 3 cardiovascular-outcomes study (NCT07551492), and an active-not-recruiting 48-participant Phase 1 adolescent-obesity study (NCT07559136). NCT07660848 separately studies ribupatide and HRS-4729 arms in recruiting Phase 2 MASH research. Hengrui also reported topline results from the 158-participant Phase 2 HRS9531-207 study in women with obesity and polycystic ovary syndrome (NCT06595797); the older registry record remains UNKNOWN, retains 144 estimated participants and has no posted results. The three global KaiNETIC records updated on 6 October 2026 now report actual enrolment of 2,530 participants without diabetes and weight-related comorbidities, 1,270 with diabetes, and 1,270 in the semaglutide-and-placebo comparator study. All three are active, not recruiting after actual December 2025 or January 2026 starts.

• Kailera Q2 2026 programme updatesponsor announcement · Published/updated: 12 August 2026 · Source review: 10 October 2026 · Source review required
• Kailera: KaiNETIC global Phase 3 enrolment completedOriginal sponsor programme announcement; not regulatory approval · Published/updated: 30 September 2026 · Source review: 10 October 2026 · Source review required
• kailera-easd-20261001Original source — see findings and limitations · Published 1 October 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored.
• ClinicalTrials.gov NCT07285902: HRS9531 versus semaglutideTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 16 December 2025 · Updated 27 February 2026Start 25 December 2025 (actual) · Primary completion 1 March 2027 (estimated) · Completion 1 March 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07709910: ribupatide in obesity and knee osteoarthritisTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 17 July 2026 · Updated 17 July 2026Start 1 July 2026 (estimated) · Primary completion 1 November 2028 (estimated) · Completion 1 December 2028 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Hengrui: Phase 2 HRS9531-207 topline results in obesity with polycystic ovary syndromeOriginal source — see findings and limitations · Published 8 July 2026 · Reviewed 12 October 2026 · Complete original sponsor announcement read for trial identity, sponsor-reported topline outcomes, 158-participant enrolment and HRS9531/KAI-9531 identity; not an independent clinical assessment.
• ClinicalTrials.gov NCT06595797: Phase II ribupatide in obesity with polycystic ovary syndromeTrial registry record · Last reviewed record: Unknown · No results posted at record-status review · First posted 19 September 2024 · Updated 19 September 2024Start 1 September 2024 (estimated) · Primary completion 1 December 2025 (estimated) · Completion 1 December 2025 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06974851: Phase III ribupatide in obesity with obstructive sleep apnoeaTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 16 May 2025 · Updated 17 November 2025Start 25 July 2025 (actual) · Primary completion 1 December 2026 (estimated) · Completion 1 December 2026 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06994650: Phase III ribupatide in obesity with obstructive sleep apnoea on PAP therapyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 29 May 2025 · Updated 26 January 2026Start 13 August 2025 (actual) · Primary completion 1 December 2026 (estimated) · Completion 1 January 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07551492: Phase III ribupatide cardiovascular-outcomes studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 24 April 2026 · Updated 8 September 2026Start 29 May 2026 (actual) · Primary completion 24 May 2031 (estimated) · Completion 28 June 2031 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07559136: Phase I ribupatide in adolescents with obesityTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 30 April 2026 · Updated 28 September 2026Start 12 June 2026 (actual) · Primary completion 1 February 2027 (estimated) · Completion 1 April 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07660848: Phase II HRS-4729 and ribupatide study in MASHTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 22 June 2026 · Updated 26 August 2026Start 14 August 2026 (actual) · Primary completion 1 March 2028 (estimated) · Completion 1 July 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07284875: KaiNETIC obesity or overweight without diabetesTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 16 December 2025 · Updated 6 October 2026Start 18 December 2025 (actual) · Primary completion 1 February 2028 (estimated) · Completion 1 March 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07284901: KaiNETIC obesity or overweight with diabetesTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 16 December 2025 · Updated 6 October 2026Start 12 January 2026 (actual) · Primary completion 27 March 2028 (estimated) · Completion 24 April 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07284979: KaiNETIC ribupatide, semaglutide and placebo studyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 16 December 2025 · Updated 6 October 2026Start 30 December 2025 (actual) · Primary completion 1 March 2028 (estimated) · Completion 1 April 2028 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: Kailera reports oral results from China and plans global Phase III initiation in the first half of 2027. NCT07670884 records a recruiting 675-participant Chinese Phase 3 study of once-daily HRS9531 tablets after an actual 24 July 2026 start, with estimated completion in November 2027.

• Kailera Q2 2026 programme updatesponsor announcement · Published/updated: 12 August 2026 · Source review: 10 October 2026 · Source review required
• ClinicalTrials.gov NCT07670884: Phase III oral ribupatide in overweight or obesityTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 26 June 2026 · Updated 13 August 2026Start 24 July 2026 (actual) · Primary completion 31 October 2027 (estimated) · Completion 30 November 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: Kailera's oral programme and Hengrui's Chinese programme have different development stages. A separate Chinese sponsor-submitted Phase 3 record, NCT07528027, studies HRS-7535 for blood-pressure control in people with hypertension and overweight or obesity. It is recruiting after an actual 29 May 2026 start with 648 estimated participants.

• Kailera Q2 2026 programme updatesponsor announcement · Published/updated: 12 August 2026 · Source review: 10 October 2026 · Source review required
• kailera-easd-20261001Original source — see findings and limitations · Published 1 October 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored.
• ClinicalTrials.gov NCT07528027: HRS-7535 in hypertension with overweight or obesityTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 14 April 2026 · Updated 24 September 2026Start 29 May 2026 (actual) · Primary completion 1 December 2027 (estimated) · Completion 1 January 2028 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: Kailera reports early triple-agonist data from China and plans global Phase I in 2026. Kailera's 1 October release adds Chinese Phase 1 findings for HRS-4729. The outside-China Phase 1 remained planned for 2026, with data expected in 2027; initiation was not confirmed. NCT07660848 records a recruiting Chinese Phase 2 MASH study with separate HRS-4729, ribupatide and matching-placebo arms after an actual 14 August 2026 start.

• Kailera Q2 2026 programme updatesponsor announcement · Published/updated: 12 August 2026 · Source review: 10 October 2026 · Source review required
• kailera-easd-20261001Original source — see findings and limitations · Published 1 October 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored.
• ClinicalTrials.gov NCT07660848: Phase II HRS-4729 and ribupatide study in MASHTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 22 June 2026 · Updated 26 August 2026Start 14 August 2026 (actual) · Primary completion 1 March 2028 (estimated) · Completion 1 July 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: Hansoh reports Chinese acceptance of its weight-management application for a weekly GLP-1/GIP injection. Acceptance is not marketing approval. Hansoh's 2 October sponsor announcement reports a 48-week randomized, double-blind, placebo-controlled Chinese Phase III LIGHTEN study in 604 adults with overweight or obesity. It reports 90.1% completion and, under the efficacy estimand, mean body-weight changes of -12.5%, -17.5% and -19.3% for weekly olatorepatide 5 mg, 10 mg and 15 mg versus -2.7% for placebo. Under the treatment-regimen estimand it reports -11.8%, -17.0% and -18.7% versus -2.5%.

• Olatorepatide Chinese NDA acceptanceOriginal Hansoh sponsor announcement; Chinese application acceptance, not regulatory approval · Published/updated: 4 June 2026 · Source review: 12 October 2026 · Source review required
• Hansoh: EASD 2026 LIGHTEN Phase III olatorepatide presentationOriginal source — see findings and limitations · Published 2 October 2026 · Reviewed 12 October 2026 · Complete original sponsor announcement read for the Chinese LIGHTEN Phase III design, participant count, completion, estimands, group-level weight changes and sponsor-reported gastrointestinal event rates; not automatically content-monitored.

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

As reported by the cited source: The EMBRAZE paper reports less lean-mass loss with the combination over 24 weeks; exploratory physical-function measures showed no notable group differences.

• Apitegromab with tirzepatide: EMBRAZE Phase 2 paperOriginal peer-reviewed trial; complete Europe PMC JATS copy · Published/updated: 8 June 2026 · Source review: 9 October 2026 · Source review required
• Scholar Rock current pipeline (date not verified)Original source — see findings and limitations · Published Not stated by the source · Reviewed 30 September 2026 · Extracted text reviewed; direct retrieval blocked (HTTP 403); not automatically content-monitored.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Regeneron reported less lean-mass loss with low-dose trevogrumab plus semaglutide. At 52 weeks, DXA lean-mass change was -4.2% with 75 mg versus -7.3% with placebo plus semaglutide. MRI thigh-muscle volume is a separate measure. Further Phase 2 research in older adults is planned.

• COURAGE Phase 2 body-composition findingssponsor announcement · Published/updated: 17 September 2025 · Source review: 9 October 2026 · Source review required
• regeneron-courage-20261001Original source — see findings and limitations · Published 1 October 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored. Direct retrieval failed; primary-page search retrieval was read.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Hengrui describes HRS-1596 as a GLP-1/GIP dual agonist being developed as a potential once-weekly oral treatment. ClinicalTrials.gov lists a Chinese Phase I study as not yet recruiting. Hengrui announced a proposed licence to Novo Nordisk outside Greater China; closing had not been confirmed by the reviewed evidence.

• Hengrui: HRS-1596 licence and Phase I readiness (official Chinese announcement)original sponsor announcement · Published/updated: 29 September 2026 · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov NCT07841860Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 25 September 2026 · Updated 25 September 2026Start 1 September 2026 (estimated) · Primary completion 1 December 2026 (estimated) · Completion 1 May 2027 (estimated)Medical evidence summary reviewed 30 September 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Hengrui: HRS-1596 licence and Phase I readiness (official Chinese announcement)Original source — see findings and limitations · Published 29 September 2026 · Reviewed 9 October 2026 · Official original Chinese announcement read for Phase I permission, investigational weekly oral potential and proposed licence closing. Replaces blocked English monitoring endpoint; no new trial-start or closing assertion.

Evidence summary reviewed 7 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Chugai says Roche discontinued obesity development of the anti-latent-myostatin antibody after an interim assessment of the Phase II GYMINDA combination study made its pre-specified clinically meaningful weight-loss objective unlikely. Rights are being returned to Chugai; possible work in spinal muscular atrophy is a separate indication. A separate Phase 1 record studies emugrobart effects on insulin sensitivity, muscle composition and muscle function in 30 estimated participants with type 2 diabetes and overweight or obesity. It is active, not recruiting after an actual 30 September 2025 start and actual 14 September 2026 primary completion; overall completion remains estimated for 28 February 2027.

• Chugai: discontinuation of emugrobart obesity developmentoriginal developer announcement · Published/updated: 28 September 2026 · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov NCT06965413 (GYMINDA)Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 11 May 2025 · Updated 9 September 2026Start 5 May 2025 (actual) · Primary completion 3 September 2026 (actual) · Completion 31 March 2027 (estimated)Medical evidence summary reviewed 30 September 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07137585: emugrobart insulin-sensitivity and muscle-composition studyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 22 August 2025 · Updated 29 September 2026Start 30 September 2025 (actual) · Primary completion 14 September 2026 (actual) · Completion 28 February 2027 (estimated)Medical evidence summary reviewed 7 October 2026 · Record status reviewed 7 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Roche for Patients: RO7204239 insulin-sensitivity and muscle-composition studyOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 7 October 2026 · Official sponsor study page reviewed for study identity and endpoints; publication and update dates were not verified and the page is not automatically monitored.

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Enveda describes ENV-308 as an investigational once-daily oral small molecule designed to mimic Lac-Phe and support weight and metabolic maintenance after GLP-1 treatment. The reported first-human study assessed safety, tolerability and drug behaviour in healthy volunteers; it did not test weight loss, body composition or post-GLP-1 maintenance. A Phase II maintenance study is planned.

• Enveda: Phase 1 ENV-308 results and planned post-GLP-1 studyoriginal developer announcement · Published/updated: 18 August 2026 · Source review: 9 October 2026 · Source review required

Evidence summary reviewed 30 September 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Boehringer Ingelheim, working with Gubra, is developing an injectable GLP-1/GIP/NPY2 receptor agonist for obesity or overweight. Its Phase 2 study records 344 actual participants and began on 30 June 2026. Completion is estimated in 2027; no results are posted. A separate Phase 1 dose-titration study remains recruiting.

• Boehringer: Phase 2 announcementOriginal source — see findings and limitations · Published 16 July 2026 · Reviewed 30 September 2026 · Primary evidence read; not automatically content-monitored.
• ClinicalTrials.gov NCT07662122 — updated 2026-09-29Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 23 June 2026 · Updated 29 September 2026Start 30 June 2026 (actual) · Primary completion 26 June 2027 (estimated) · Completion 10 July 2027 (estimated)Medical evidence summary reviewed 30 September 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07754474 — updated 2026-09-23Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 10 August 2026 · Updated 23 September 2026Start 1 September 2026 (actual) · Primary completion 21 June 2027 (estimated) · Completion 21 June 2027 (estimated)Medical evidence summary reviewed 30 September 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records an active, not recruiting Phase 2 study (record updated 9 October 2026) of macupatide and eloralintide, alone or in combination, in an estimated 200 adults with obesity or overweight and type 2 diabetes. It records an actual 16 October 2025 start and estimated March 2027 primary completion. A separate Japanese Phase 1 study remains not yet recruiting and has only an estimated October 2026 start.

• ClinicalTrials.gov NCT07765511 — planned Phase 1 studyTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 14 August 2026 · Updated 14 August 2026Start 1 October 2026 (estimated) · Primary completion 1 June 2027 (estimated) · Completion 1 June 2027 (estimated)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07215559 — lifecycle reviewed 9 October 2026Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 10 October 2025 · Updated 9 October 2026Start 16 October 2025 (actual) · Primary completion 1 March 2027 (estimated) · Completion 1 May 2027 (estimated)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A subcutaneous anti-myostatin/GDF11 antibody being studied in adults with overweight or obesity. iBio announced first-participant dosing on 2 June 2026. NCT07487376 records a randomised single-ascending-dose trial with 32 estimated participants and no posted results.

• ibio600-first-dose-20260602Original source — see findings and limitations · Published 2 June 2026 · Reviewed 1 October 2026 · Primary evidence read for this factual update; not automatically content-monitored.
• ibio600-registryTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 23 March 2026 · Updated 29 May 2026Start 24 May 2026 (actual) · Primary completion 1 May 2027 (estimated) · Completion 1 May 2027 (estimated)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A long-acting GLP-1/GIP co-agonist peptide prodrug being studied in adults with obesity. MBX reported preliminary blinded eight-week data from a small Phase 1 cohort on 11 May 2026. The registry remained recruiting at its 9 June 2026 update and has no posted results.

• MBX Biosciences obesity portfolio updateOriginal source — see findings and limitations · Published 11 May 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for Phase 1 design, preliminary blinded data and planned dosing; not automatically content-monitored.
• ClinicalTrials.gov NCT07142707Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 27 August 2025 · Updated 9 June 2026Start 3 September 2025 (actual) · Primary completion 30 October 2026 (estimated) · Completion 30 October 2026 (estimated)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

An RNA-interference programme designed to reduce hepatic INHBE expression and Activin E. Arrowhead reported interim Phase 1/2a metabolic and body-composition findings on 27 May 2026. The registry remained recruiting at its 25 September update and has no posted results.

• Arrowhead ARO-INHBE EASL 2026 updateOriginal source — see findings and limitations · Published 27 May 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for interim Phase 1/2a findings and limitations; not automatically content-monitored.
• ClinicalTrials.gov NCT06700538Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 22 November 2024 · Updated 25 September 2026Start 4 December 2024 (actual) · Primary completion 17 September 2027 (estimated) · Completion 17 January 2028 (estimated)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

An oral non-incretin small-molecule ACSL5 inhibitor licensed by Novo Nordisk from Lexicon. The companies announced first-in-human Phase 1 initiation on 23 March 2026 in people with overweight or obesity; completion was expected in the first quarter of 2027.

• Lexicon and Novo Nordisk LX9851 Phase 1 initiationOriginal source — see findings and limitations · Published 23 March 2026 · Reviewed 1 October 2026 · Original joint sponsor announcement read for mechanism, initiation and planned completion; not automatically content-monitored.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A once-weekly investigational GLP-1/GIP/glucagon receptor triple agonist. Neurocrine announced first-in-human Phase 1 initiation on 7 August 2026 and described intended later fixed-dose-combination development with its separate Phase 1 CRF2 agonist NBIP-2118.

• Neurocrine NBIP-1968 Phase 1 initiationOriginal source — see findings and limitations · Published 7 August 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for Phase 1 initiation, formulation and proposed combination; not automatically content-monitored.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A once-daily oral, peripherally restricted CB1 inverse agonist. Corbus reported CANYON-1 topline Phase 1b results on 14 September 2026 after 12 weeks of treatment. A Phase 2 monotherapy study was planned for the first half of 2027, not yet treated as started. The registry update posted on 9 October 2026 records CANYON-1 as completed with 254 actual participants and actual primary and study completion on 3 August 2026.

• Corbus CANYON-1 topline resultsOriginal source — see findings and limitations · Published 14 September 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for study design, topline findings, adverse events and planned Phase 2; not automatically content-monitored.
• ClinicalTrials.gov NCT07310901 — lifecycle reviewed 9 October 2026Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 30 December 2025 · Updated 9 October 2026Start 4 December 2025 (actual) · Primary completion 3 August 2026 (actual) · Completion 3 August 2026 (actual)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

An investigational daily oral tablet intended to create a transient lining in the small intestine and alter nutrient absorption. On 15 September 2026 Syntis reported observations from the randomised, double-blind, placebo-controlled 28-day multiple-ascending-dose portion in 23 adults with overweight or obesity. The company reported greater weight loss than placebo in each dose cohort and changes in satiety-related hormones; a Phase 2 study was planned for 2027, not treated as started.

• Syntis SYNT-101 initial Phase 1/1b dataOriginal source — see findings and limitations · Published 16 July 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for single-dose findings, mechanism and planned multiple-dose reporting; not automatically content-monitored.
• Syntis SYNT-101 28-day Phase 1/1b multiple-dose resultsOriginal source — see findings and limitations · Published 15 September 2026 · Reviewed 1 October 2026 · Original sponsor announcement read for the 28-day multiple-dose cohort and planned Phase 2; not automatically content-monitored.

Evidence summary reviewed 1 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A GIP-receptor-antagonist/GLP-1-receptor-agonist fusion protein being studied for weight maintenance after semaglutide-associated weight loss. Alveus announced first-patient dosing in the Phase 2 PRESERVE study on 14 September 2026; the registry showed recruiting with an actual 10 August 2026 start at its 28 September update.

• Alveus PRESERVE Phase 2 initiationOriginal source — see findings and limitations · Published 14 September 2026 · Reviewed 1 October 2026 · Original sponsor-distributed announcement read for study population, design and initiation; not automatically content-monitored.
• ClinicalTrials.gov NCT07837973Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 24 September 2026 · Updated 28 September 2026Start 10 August 2026 (actual) · Primary completion 24 August 2027 (estimated) · Completion 24 August 2027 (estimated)Medical evidence summary reviewed 1 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Sciwind reported on 6 March 2026 that China's NMPA approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. This is a China-specific authorisation, not a UK approval. A separate sponsor-submitted Chinese Phase 3 study in 360 people with obesity and knee osteoarthritis is recruiting after an actual 3 August 2026 start; it has no posted results.

• Sciwind ecnoglutide China NMPA approval announcementOriginal source — see findings and limitations · Published 6 March 2026 · Reviewed 2 October 2026 · Original sponsor announcement read in full for the China indication and approval boundary; not automatically content-monitored.
• ClinicalTrials.gov NCT07734311Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 29 July 2026 · Updated 31 August 2026Start 3 August 2026 (actual) · Primary completion 31 May 2028 (estimated) · Completion 30 June 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Innovent reported on 27 June 2025 that China's NMPA approved mazdutide for chronic weight management in adults with overweight or obesity. This is a China-specific authorisation, not a UK approval. Separately, the investigator-sponsored NCT07517042 record describes a recruiting Chinese maintenance study after an actual 10 June 2026 start. It compares reduced-dose weekly mazdutide, intensive lifestyle support, their combination and standard health education after initial mazdutide-assisted weight loss.

• Innovent mazdutide China NMPA approval announcementOriginal source — see findings and limitations · Published 27 June 2025 · Reviewed 2 October 2026 · Original sponsor page and indexed official-page text reviewed for the China approval and indication boundary; the public page is JavaScript-rendered and is not automatically content-monitored.
• ClinicalTrials.gov NCT07517042: ASCEND-1 mazdutide maintenance studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 8 April 2026 · Updated 15 September 2026Start 10 June 2026 (actual) · Primary completion 1 December 2028 (estimated) · Completion 1 December 2028 (estimated)Medical evidence summary reviewed 11 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis reported injectable ASC36 Phase 1 initiation on 10 August 2026. Monthly-to-quarterly dosing is a development objective, not an established regimen.

• Ascletis ASC36 and ASC36_35FDC Phase 1 initiation announcementOriginal source — see findings and limitations · Published 10 August 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for initiation, formulation, design and animal-evidence limitations; not automatically content-monitored.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis reported Phase 1 initiation on 10 August 2026 for an investigational monthly injectable co-formulation targeting amylin, GLP-1 and GIP receptors.

• Ascletis ASC36 and ASC36_35FDC Phase 1 initiation announcementOriginal source — see findings and limitations · Published 10 August 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for initiation, formulation, design and animal-evidence limitations; not automatically content-monitored.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a recruiting Phase 1 study of investigational monthly ASC35 Injection B, with an actual 27 August 2026 start, estimated enrolment of 84 and estimated June 2027 completion.

• ClinicalTrials.gov NCT07842640Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 25 September 2026 · Updated 25 September 2026Start 27 August 2026 (actual) · Primary completion 1 June 2027 (estimated) · Completion 1 June 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Arrowhead's current pipeline records a recruiting first-in-human study in adults with obesity. It evaluates ARO-ALK7 alone and, separately, with tirzepatide; an estimated completion date is not treated as completed research.

• Arrowhead current pipeline: ARO-ALK7Original source — see findings and limitations · Published Not stated by the source · Reviewed 2 October 2026 · Current original sponsor pipeline read for recruiting status, Phase 1/2a design, combination arm and the distinction between estimates and completed events; not automatically content-monitored.
• Arrowhead ARO-ALK7 Phase 1/2a initiationPreclinical research — see limitations · Published 2 June 2025 · Reviewed 2 October 2026 · Original sponsor announcement read for first dosing and study design; preclinical claims retained as preclinical; not automatically content-monitored.
• ClinicalTrials.gov NCT06937203Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 22 April 2025 · Updated 8 July 2026Start 9 May 2025 (actual) · Primary completion 1 February 2027 (estimated) · Completion 1 February 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a Chinese Phase 2 study of once-weekly subcutaneous MWN105 in 120 non-diabetic participants with overweight or obesity. It started on 3 September 2025 and completed on 16 April 2026.

• ClinicalTrials.gov NCT07804810Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 4 September 2026 · Updated 4 September 2026Start 3 September 2025 (actual) · Primary completion 21 March 2026 (actual) · Completion 16 April 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a completed Chinese Phase 1 study of oral IBI3032 tablets: single ascending doses in healthy participants and four weeks of multiple ascending doses in participants with overweight or obesity.

• ClinicalTrials.gov NCT07160400Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 8 September 2025 · Updated 11 September 2026Start 4 September 2025 (actual) · Primary completion 6 August 2026 (actual) · Completion 10 August 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a recruiting Chinese Phase 2 study comparing three once-weekly HDM1005 dose groups with tirzepatide in adults with obesity without diabetes. Actual study start was 31 March 2026; estimated enrolment is 372.

• ClinicalTrials.gov NCT07521631Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 13 April 2026 · Updated 13 April 2026Start 31 March 2026 (actual) · Primary completion 4 February 2027 (estimated) · Completion 23 July 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted SLIM-1 registry record describes a four-week Phase 1 comparison of a subcutaneous semaglutide implant with weekly Wegovy injections in 20 participants with overweight or obesity.

• ClinicalTrials.gov NCT07430059Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 24 February 2026 · Updated 30 June 2026Start 1 July 2026 (estimated) · Primary completion 1 December 2026 (estimated) · Completion 1 January 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Novo Nordisk and United Biotechnology sponsor-reported evidence describes once-weekly injectable UBT251 as a GLP-1/GIP/glucagon triple agonist. A Chinese Phase 2 obesity study reported up to 19.7% mean weight loss after 24 weeks; Novo's later pipeline presentation records a separate global Phase 1b/2a obesity study as ongoing.

• Novo Nordisk and United Biotechnology: UBT251 Chinese Phase 2 topline resultsOriginal source — see findings and limitations · Published 24 February 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for formulation, mechanism, Chinese Phase 2 design, 24-week sponsor-reported result, partnership responsibilities and the separate global Phase 1b/2a plan; not automatically content-monitored.
• Novo Nordisk Capital Markets Day 2026 obesity presentationOriginal source — see findings and limitations · Published 21 September 2026 · Reviewed 2 October 2026 · Original sponsor pipeline presentation read for the ongoing global Phase 1b/2a obesity study, Chinese Phase 2 context and planned mid-2027 Phase 3 timing; forward-looking dates remain plans; not automatically content-monitored.
• ClinicalTrials.gov NCT07177469Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 17 September 2025 · Updated 24 September 2026Start 14 March 2025 (actual) · Primary completion 22 October 2025 (actual) · Completion 19 November 2025 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

SanegeneBio reports that the first participant was dosed in January 2026 in a Chinese Phase 1 study of subcutaneous SGB-7342. The investigational GalNAc-conjugated siRNA targets INHBE messenger RNA; the registered study is a single-ascending-dose safety, tolerability, pharmacokinetic and pharmacodynamic study in adults with obesity or overweight.

• SanegeneBio: first participant dosed in Phase 1 SGB-7342 trialPreclinical research — see limitations · Published 13 January 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for the first-participant event, formulation, INHBE RNAi mechanism and Phase 1 design; sponsor preclinical observations remain labelled preclinical; not automatically content-monitored.
• ClinicalTrials.gov NCT07324850Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 8 January 2026 · Updated 9 January 2026Start 12 January 2026 (estimated) · Primary completion 28 October 2026 (estimated) · Completion 14 April 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

AbbVie's sponsor-submitted NCT07752979 record, updated 6 October 2026, remains a recruiting Phase 2 dose-finding study of subcutaneous ABBV-295 versus placebo in adults with obesity or overweight and weight-related conditions. It records an actual 4 August 2026 start, 360 estimated participants and estimated March 2028 completion. The 30 September sponsor announcement reports separate Phase 1 findings.

• AbbVie detailed ABBV-295 Phase 1 announcementOriginal source — see findings and limitations · Published 30 September 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for study design, reported cohort size, dosing intervals, findings, approval boundary and planned Phase 2 development; not automatically content-monitored.
• ClinicalTrials.gov NCT06144684Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 22 November 2023 · Updated 15 January 2026Start 29 November 2023 (actual) · Primary completion 5 January 2026 (actual) · Completion 5 January 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07752979: ABBV-295 Phase 2Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 7 August 2026 · Updated 8 October 2026Start 4 August 2026 (actual) · Primary completion 1 March 2028 (estimated) · Completion 1 March 2028 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07752979: 6 October 2026 record reviewTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 7 August 2026 · Updated 8 October 2026Start 4 August 2026 (actual) · Primary completion 1 March 2028 (estimated) · Completion 1 March 2028 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Oral ASC30 is an investigational once-daily small-molecule GLP-1 receptor agonist. The sponsor reported the first participant dosed in the global Phase III AURORA programme. AURORA-1 studies adults with obesity or overweight without type 2 diabetes and records 3,003 estimated participants; AURORA-2 studies adults with obesity or overweight and type 2 diabetes and records 1,560 estimated participants. Both sponsor-submitted records are recruiting, have actual August 2026 starts, use 20 mg, 40 mg and 60 mg maintenance-dose groups versus placebo over 72 weeks, and have no posted results. The earlier completed US Phase 2 study and sponsor-reported results remain separate evidence.

• Ascletis: first participant dosed in ASC30 AURORA Phase III programmeOriginal Ascletis sponsor announcement; first dosing and programme plans, not trial results or marketing authorisation · Published/updated: 30 August 2026 · Source review: 12 October 2026 · Source review required
• Ascletis ADA 2026 programme announcementOriginal source — see findings and limitations · Published 30 April 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for the oral Phase 2 presentation and formulation distinction; not automatically content-monitored.
• ClinicalTrials.gov NCT07002905Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 4 June 2025 · Updated 15 December 2025Start 3 July 2025 (actual) · Primary completion 8 December 2025 (actual) · Completion 8 December 2025 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07743463: ASC30 AURORA-1Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 3 August 2026 · Updated 16 September 2026Start 31 August 2026 (actual) · Primary completion 1 July 2028 (estimated) · Completion 1 July 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07743450: ASC30 AURORA-2Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 3 August 2026 · Updated 16 September 2026Start 28 August 2026 (actual) · Primary completion 1 July 2028 (estimated) · Completion 1 July 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis reported a 65-participant US Phase 2 study of two subcutaneous depot formulations on 10 March 2026. Formulation A1 was given monthly three times; the sponsor described less-frequent maintenance dosing as a development possibility, not an authorised regimen.

• Ascletis ASC30 depot Phase 2 announcementOriginal source — see findings and limitations · Published 10 March 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for participant count, formulation-specific exposure, dosing, sponsor-reported results and planned maintenance interpretation; not automatically content-monitored.
• ClinicalTrials.gov NCT06679959Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 8 November 2024 · Updated 26 June 2026Start 16 September 2024 (actual) · Primary completion 26 March 2026 (actual) · Completion 26 March 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Terns reported 12-week Phase 2 FALCON findings in October 2025. Its subsequent quarterly filing states that the company would not advance TERN-601 or invest in other metabolic assets, so it is retained as a stopped programme rather than an advancing oral GLP-1 candidate.

• Terns TERN-601 Phase 2 topline announcementOriginal source — see findings and limitations · Published 21 October 2025 · Reviewed 2 October 2026 · Original sponsor result page identified and search-retrieved, but direct page retrieval returned HTTP 401 in this run; no automatic baseline is claimed.
• Terns 2025 Q3 Form 10-QOriginal source — see findings and limitations · Published 10 November 2025 · Reviewed 2 October 2026 · Original sponsor filing read through indexed primary text for the decision not to advance TERN-601 or invest in other metabolic assets; direct retrieval was incomplete, so the limitation remains explicit and no baseline is claimed.
• ClinicalTrials.gov NCT06854952Trial registry record · Last reviewed record: Completed · Results posted; outcomes need separate assessment · First posted 3 March 2025 · Updated 10 August 2026Start 7 March 2025 (actual) · Primary completion 19 August 2025 (actual) · Completion 19 September 2025 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Lilly's sponsor page and registry record an active, not recruiting Phase 2 study of bimagrumab, tirzepatide and their combination in 252 adults with obesity or overweight without diabetes. Primary completion was 16 January 2026, while overall study completion remains estimated for January 2027. A separate completed Phase 2 BELIEVE study randomized 507 adults to bimagrumab, semaglutide, their combinations or placebo. The registry has posted results, and the peer-reviewed March 2026 paper reports substantial weight and fat-mass reductions with the combination while largely preserving lean mass relative to semaglutide alone.

• Lilly trial page J4Z-MC-GIDFOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 2 October 2026 · Original sponsor trial page read for completed enrolment, Phase 2 design, 252-participant target and study dates; publication and update dates are not stated and remain unknown; not automatically content-monitored.
• ClinicalTrials.gov NCT06643728Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 16 October 2024 · Updated 26 May 2026Start 21 October 2024 (actual) · Primary completion 16 January 2026 (actual) · Completion 1 January 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Lilly ADA 2025 bimagrumab programme announcementOriginal source — see findings and limitations · Published 29 May 2025 · Reviewed 2 October 2026 · Original sponsor announcement read for the separate BELIEVE programme and Lilly's body-composition research rationale; not automatically content-monitored.
• ClinicalTrials.gov NCT05616013Trial registry record · Last reviewed record: Completed · Results posted; outcomes need separate assessment · First posted 14 November 2022 · Updated 8 July 2026Start 16 November 2022 (actual) · Primary completion 16 May 2024 (actual) · Completion 14 June 2025 (actual)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Nature Medicine BELIEVE randomized Phase 2 paperPeer-reviewed randomized Phase 2 research — see limitations · Published 2 March 2026 · Reviewed 9 October 2026 · Complete peer-reviewed paper read for design, participant count, body-weight, fat-mass, lean-mass, safety and functional-outcome limitations. Outside automatic content monitoring.
• Lilly EASD 2026 BELIEVE withdrawal-extension presentation listingSponsor congress presentation listing — see limitations · Published Not stated by the source · Reviewed 9 October 2026 · Original sponsor congress page read for the 30 September 2026 withdrawal-extension presentation listing. Page publication and update dates were not verified; the listing is context, not an independently assessed efficacy claim and is outside automatic monitoring.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a recruiting Chinese Phase 3 placebo-controlled study of once-daily oral DA-302168S, described there as a small-molecule GLP-1 receptor agonist, in adults with overweight or obesity. Actual study start was 19 June 2026; estimated enrolment is 840.

• ClinicalTrials.gov NCT07629544Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 5 June 2026 · Updated 6 August 2026Start 19 June 2026 (actual) · Primary completion 9 July 2027 (estimated) · Completion 19 October 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a completed first-in-human Phase 1 study of once-weekly subcutaneous NNC0662-0419 in 100 participants with overweight or obesity. It used single- and multiple-ascending-dose cohorts and completed on 26 July 2025. The complete current registry search also finds two active, not-recruiting Phase 2 obesity studies: NCT07184632 is a 224-participant dose-finding study and NCT07639021 is a 233-participant dose-escalation study. A separate recruiting 270-participant Phase 2 study, NCT07415954, evaluates glycaemic control in type 2 diabetes. Two additional Phase 1 records cover single-dose pharmacokinetics across Japanese, Chinese and non-Asian participants and oral-contraceptive pharmacokinetics and gastric emptying.

• ClinicalTrials.gov NCT06737536Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 17 December 2024 · Updated 19 September 2025Start 18 December 2024 (actual) · Primary completion 26 July 2025 (actual) · Completion 26 July 2025 (actual)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07101783: NNC0662-0419 pharmacokinetic studyTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 3 August 2025 · Updated 23 December 2025Start 1 August 2025 (actual) · Primary completion 31 October 2025 (actual) · Completion 31 October 2025 (actual)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07184632: NNC0662-0419 obesity dose-finding studyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 22 September 2025 · Updated 7 May 2026Start 1 October 2025 (actual) · Primary completion 14 December 2026 (estimated) · Completion 14 December 2026 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07415954: NNC0662-0419 type 2 diabetes studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 17 February 2026 · Updated 11 September 2026Start 17 April 2026 (actual) · Primary completion 3 September 2027 (estimated) · Completion 1 October 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07525791: NNC0662-0419 supportive Phase 1 studyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 13 April 2026 · Updated 30 September 2026Start 7 April 2026 (actual) · Primary completion 2 May 2027 (estimated) · Completion 18 June 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07639021: NNC0662-0419 dose-escalation studyTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 10 June 2026 · Updated 16 September 2026Start 9 June 2026 (actual) · Primary completion 14 June 2027 (estimated) · Completion 14 June 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry describes DR10624 as a subcutaneous Fc-fusion tri-agonist targeting GLP-1, glucagon and FGF21 receptors. Its 153-participant first-in-human Phase 1 study completed on 31 January 2025.

• ClinicalTrials.gov NCT05378893Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 18 May 2022 · Updated 4 February 2025Start 22 June 2022 (actual) · Primary completion 10 October 2024 (actual) · Completion 31 January 2025 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry describes a Chinese first-in-human Phase 1 study of subcutaneous CMS-D008 with single-dose, multiple-dose and expansion cohorts in healthy adults and adults with overweight or obesity.

• ClinicalTrials.gov NCT07518589Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 8 April 2026 · Updated 8 April 2026Start 2 April 2026 (estimated) · Primary completion 24 November 2027 (estimated) · Completion 10 December 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records 239 older adults with obesity enrolled in PLATEAU, a Phase 2 study of daily oral enobosarm 3 mg or placebo alongside weekly semaglutide. The study evaluates total body weight, lean and fat mass, physical function, bone mineral density and safety; its registry status is active, not recruiting.

• ClinicalTrials.gov NCT07446998 (PLATEAU)Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 3 March 2026 · Updated 4 September 2026Start 26 March 2026 (actual) · Primary completion 1 October 2027 (estimated) · Completion 1 December 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Veru PLATEAU full-enrolment announcementOriginal source — see findings and limitations · Published 27 July 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for completed enrolment, trial design, planned interim and final timing, earlier QUALITY context and the explicit non-endorsement boundary for Novo Nordisk's clinical supply; not automatically content-monitored.
• Veru fiscal 2026 Q3 PLATEAU updateOriginal source — see findings and limitations · Published 10 August 2026 · Reviewed 2 October 2026 · Original sponsor update read for actual 239-person enrolment and still-planned Q1 and Q4 2027 analyses; sponsor claims are attributed and not treated as regulatory findings; not automatically content-monitored.
• ClinicalTrials.gov NCT06282458 (QUALITY)Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 28 February 2024 · Updated 17 September 2025Start 29 April 2024 (actual) · Primary completion 11 April 2025 (actual) · Completion 22 August 2025 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a 760-participant Chinese Phase 3 study of once-weekly subcutaneous MWN109 for 52 weeks. The record remains not yet recruiting and its estimated 1 September 2026 start is not treated as first dosing. A separate 120-participant Phase 2 injection study is registry-completed with no posted results.

• ClinicalTrials.gov NCT07778693Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 21 August 2026 · Updated 21 August 2026Start 1 September 2026 (estimated) · Primary completion 1 September 2027 (estimated) · Completion 1 November 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07791654Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 28 August 2026 · Updated 28 August 2026Start 23 August 2025 (actual) · Primary completion 21 March 2026 (actual) · Completion 21 March 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

One sponsor-submitted Chinese Phase 2 record reports 255 participants completed 20 weeks of once-daily MWN109 tablets. A distinct 71-participant weight-loss-maintenance study compares daily and weekly oral dosing and remains active, not recruiting.

• ClinicalTrials.gov NCT07791524Trial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 28 August 2026 · Updated 28 August 2026Start 5 January 2026 (actual) · Primary completion 9 July 2026 (actual) · Completion 9 July 2026 (actual)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07804797Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 4 September 2026 · Updated 4 September 2026Start 2 March 2026 (actual) · Primary completion 1 September 2026 (estimated) · Completion 1 September 2026 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry describes first-in-human single- and multiple-dose subcutaneous MWN110 research in healthy participants and people with overweight or obesity. It remains not yet recruiting with estimated enrolment of 103.

• ClinicalTrials.gov NCT07779980Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 21 August 2026 · Updated 24 August 2026Start 26 August 2026 (estimated) · Primary completion 1 August 2027 (estimated) · Completion 1 August 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records an actual 25 August 2026 start for a recruiting Chinese Phase 1b study of oral TQF3250 in people with type 2 diabetes and overweight or obesity. A separate weight-management study remains not yet recruiting.

• Sino Biopharmaceutical TQF3250 clinical-trial clearance announcementOriginal source — see findings and limitations · Published 4 December 2025 · Reviewed 2 October 2026 · Original sponsor announcement read for formulation, mechanism and clinical-trial clearance boundaries; not automatically content-monitored.
• ClinicalTrials.gov NCT07747857Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 5 August 2026 · Updated 28 August 2026Start 25 August 2026 (actual) · Primary completion 1 June 2027 (estimated) · Completion 1 July 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07798284Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 1 September 2026 · Updated 1 September 2026Start 1 September 2026 (estimated) · Primary completion 1 April 2027 (estimated) · Completion 1 April 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted registry records a recruiting 75-participant South Korean Phase 2a dose-finding study of once-daily oral KDS2010 for 12 weeks in adults with overweight or obesity, with an actual 29 July 2025 start.

• NeuroBiogen KDS2010 Phase 2a IND announcementOriginal source — see findings and limitations · Published 4 September 2024 · Reviewed 2 October 2026 · Original sponsor page read for Phase 2a IND history; not automatically content-monitored.
• ClinicalTrials.gov NCT07009171Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 6 June 2025 · Updated 24 June 2026Start 29 July 2025 (actual) · Primary completion 31 January 2027 (estimated) · Completion 30 June 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

OrsoBio reported on 16 December 2025 that 55 adults with obesity completed a 24-week comparison of once-daily oral TLC-6740 plus low-dose tirzepatide versus tirzepatide alone. The broader registry record remains active, not recruiting and has no posted results.

• OrsoBio TLC-6740 and tirzepatide topline announcementOriginal source — see findings and limitations · Published 16 December 2025 · Reviewed 2 October 2026 · Original sponsor announcement read for the 55-participant comparison, sponsor-reported findings, safety wording and Phase 2b plan; not automatically content-monitored.
• ClinicalTrials.gov NCT05822544Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 20 April 2023 · Updated 21 August 2026Start 22 April 2023 (actual) · Primary completion 1 September 2026 (estimated) · Completion 1 January 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Biophytis describes a 164-participant Phase 2 OBA study of oral BIO101 or placebo alongside semaglutide, focused on lower-limb muscle strength during weight loss and a later weight-regain assessment after semaglutide discontinuation.

• Biophytis OBA timing updateOriginal source — see findings and limitations · Published 31 August 2026 · Reviewed 2 October 2026 · Original sponsor update read for the later Q1 2027 planned study start; not automatically content-monitored.
• Biophytis OBA protocol-amendment announcementOriginal source — see findings and limitations · Published 9 September 2026 · Reviewed 2 October 2026 · Original sponsor announcement read for the planned post-semaglutide weight-regain follow-up; not automatically content-monitored.
• ClinicalTrials.gov NCT07411378Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 13 February 2026 · Updated 13 February 2026Start 1 July 2026 (estimated) · Primary completion 1 June 2027 (estimated) · Completion 1 August 2027 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 5 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Three investigator-led registry records study semaglutide beyond its established weight-management use: weekly semaglutide versus placebo for chronic low-back-pain severity; pre-operative semaglutide and behavioural support before hip or knee arthroplasty; and semaglutide plus a levonorgestrel intrauterine device and structured weight loss for conservative treatment of endometrial atypical hyperplasia or grade 1 endometrial cancer. Six records first posted on 5 October add five Phase 4 metabolic-and-bariatric-surgery studies from one Egyptian unit and the Canadian PIVOT Phase 4 study in advanced kidney disease. The surgical records separately study pre-operative use at BMI 60 kg/m² or higher, recurrent weight gain, semaglutide around conversion surgery, tapering versus abrupt discontinuation, and immediate versus criterion-triggered treatment. PIVOT compares semaglutide plus virtual coaching with usual care while studying weight and kidney-transplant access.

• ClinicalTrials.gov NCT07731256: Semaglutide for Low Back PainTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 28 July 2026 · Updated 28 July 2026Start 1 February 2027 (estimated) · Primary completion 1 January 2031 (estimated) · Completion 1 September 2031 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07755085: GLP-1s in Hip and Knee ArthroplastyTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 10 August 2026 · Updated 10 August 2026Start 1 October 2026 (estimated) · Primary completion 1 June 2028 (estimated) · Completion 1 December 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07820358: Semaglutide, Weight Loss, and LNG-IUDTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 15 September 2026 · Updated 1 October 2026Start 1 January 2027 (estimated) · Primary completion 31 December 2028 (estimated) · Completion 31 December 2031 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07858331: semaglutide and virtual support for kidney transplant accessTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 January 2027 (estimated) · Primary completion 1 January 2029 (estimated) · Completion 1 January 2029 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07859137: pre-operative semaglutide before metabolic and bariatric surgeryTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 November 2028 (estimated) · Completion 1 November 2028 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07859150: RESURGE semaglutide after metabolic and bariatric surgeryTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 April 2029 (estimated) · Completion 1 April 2029 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07859163: semaglutide around conversion surgery after recurrent weight gainTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 April 2029 (estimated) · Completion 1 April 2029 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07859176: tapered versus abrupt semaglutide discontinuation after bariatric surgeryTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 April 2028 (estimated) · Completion 1 April 2028 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07859189: immediate versus criterion-triggered semaglutide after bariatric surgeryTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 October 2028 (estimated) · Completion 1 October 2028 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 5 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The Cleveland Clinic registry record describes a 52-week, open-label Phase 2 study in 30 adults with COPD and obesity or overweight. Twenty participants are planned to receive tirzepatide with standard care and ten standard care alone. The study measures lung function and muscle-related outcomes including grip strength, walking, sit-to-stand performance, lean mass and skeletal-muscle mitochondrial function.

• ClinicalTrials.gov NCT07747805: GLIMR COPDTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 August 2026 · Updated 5 August 2026Start 28 August 2026 (estimated) · Primary completion 15 August 2028 (estimated) · Completion 15 August 2029 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 2 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Two UNC Lineberger registry records study short pre-operative tirzepatide use in people with obesity and endometrial cancer or endometrial intraepithelial neoplasia. The 20-participant Early Phase 1 record reports an actual 27 April 2026 start and is recruiting; the separate 40-participant Phase 2 record remains not yet recruiting.

• ClinicalTrials.gov NCT07065552: Tirzepatide in Obesity-Driven Endometrial CancerTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 15 July 2025 · Updated 2 October 2026Start 27 April 2026 (actual) · Primary completion 1 July 2028 (estimated) · Completion 1 July 2028 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07078838: Tirzepatide in Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial CancerTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 22 July 2025 · Updated 28 September 2026Start 1 January 2027 (estimated) · Primary completion 1 March 2029 (estimated) · Completion 1 March 2029 (estimated)Medical evidence summary reviewed 2 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor describes oral NA-931 as a quadruple IGF-1, GLP-1, GIP and glucagon receptor agonist and reports a Phase 3 programme. A separate sponsor-submitted Phase 2 registry record plans NA-931 alone and with weekly tirzepatide in an estimated 224 adults with overweight or obesity, including body-weight, body-composition and physical-function measures.

• ClinicalTrials.gov NCT06732245: NA-931 alone and with tirzepatideTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 13 December 2024 · Updated 27 March 2026Start 15 August 2026 (estimated) · Primary completion 15 August 2027 (estimated) · Completion 15 December 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Biomed Industries NA-931 programme pageOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 3 October 2026 · Original sponsor page read for molecule description, oral formulation and sponsor-reported Phase 3 and lean-mass claims. Page publication and update dates were not independently verified; claims remain attributed and are not automatically content-monitored.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

AZD6234 is a weekly injectable selective amylin receptor agonist in AstraZeneca's research programme. The sponsor-submitted SELENE 1 record lists recruiting Phase 3 monotherapy research in adults with obesity or overweight and a weight-related condition without type 2 diabetes, with an actual 19 August 2026 start and 2,500 estimated participants. Its separate completed Phase 2b APRICUS record retains 262 actual participants and actual 3 December 2025 completion. Neither registry record has posted results.

• ClinicalTrials.gov NCT06595238: APRICUSTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 19 September 2024 · Updated 2 October 2026Start 1 October 2024 (actual) · Primary completion 3 December 2025 (actual) · Completion 3 December 2025 (actual)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• AstraZeneca portfolio announcementOriginal source — see findings and limitations · Published 30 January 2026 · Reviewed 3 October 2026 · Original sponsor text read for AZD6234 mechanism and injectable formulation. No agreement-closing event or later trial stage is inferred; update date unverified; not automatically content-monitored.
• ClinicalTrials.gov NCT07784725: SELENE 1Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 25 August 2026 · Updated 25 August 2026Start 19 August 2026 (actual) · Primary completion 11 August 2028 (estimated) · Completion 21 May 2029 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• AstraZeneca SELENE 1 study D8750C00014Original source — see findings and limitations · Published Not stated by the source · Reviewed 3 October 2026 · Original sponsor study page read for recruiting Phase 3, weekly subcutaneous formulation, study identity, estimated enrolment and completion dates. It says verified 1 August 2026; this is not treated as publication/update date. Its N/A registry identifier and absent locations remain explicit; not automatically content-monitored.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

NIDDK's NCT05713799 record describes an oral mirabegron and alpha-lipoic acid crossover pilot in adults with obesity. The 9 October 2026 update remains not yet recruiting, with its estimated start moved again to 14 October 2026, 60 estimated participants and estimated March 2030 completion. Its primary endpoint is insulin sensitivity, with metabolic and exploratory body-composition outcomes.

• ClinicalTrials.gov NCT05713799 — lifecycle reviewed 9 October 2026Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 6 February 2023 · Updated 9 October 2026Start 14 October 2026 (estimated) · Primary completion 1 March 2030 (estimated) · Completion 1 March 2030 (estimated)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

AstraZeneca's sponsor-submitted NCT07511205 record describes a Phase 1 single- and multiple-ascending-dose study of subcutaneous or intravenous AZD1043 in healthy adults living with overweight or obesity. It records recruiting overall status, an actual 30 March 2026 start and 104 estimated participants. AstraZeneca's pipeline identifies AZD1043 as an ActRII monoclonal antibody in Phase 1 obesity research.

• ClinicalTrials.gov NCT07511205Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 6 April 2026 · Updated 9 September 2026Start 30 March 2026 (actual) · Primary completion 9 April 2027 (estimated) · Completion 17 November 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• AstraZeneca clinical study D9740C00001Original source — see findings and limitations · Published Not stated by the source · Reviewed 3 October 2026 · Original sponsor study page read for study purpose and formulation; publication date unverified and page update date shown by the source; not automatically content-monitored.
• AstraZeneca pipelineOriginal source — see findings and limitations · Published 27 July 2026 · Reviewed 3 October 2026 · Original sponsor pipeline read for the ActRII monoclonal-antibody description and Phase 1 obesity placement as of 27 July 2026; page publication/update date otherwise unverified; not automatically content-monitored.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

An investigational subcutaneous INHBE-targeting GalNAc-siRNA. The INLIGHT monotherapy registry lists recruiting Phase 1/2a research with 296 estimated participants and no posted results. Wave's 23 September 2026 announcement separately reports Phase 2a initiation with tirzepatide in adults with obesity and type 2 diabetes. A post-incretin weight-maintenance trial remains planned for the second half of 2026.

• Wave: WVE-007 with tirzepatide Phase 2a initiationOriginal source — see findings and limitations · Published 23 September 2026 · Reviewed 3 October 2026 · Original sponsor announcement read for INHBE mechanism, subcutaneous formulation, separate Phase 2a combination initiation, monotherapy, planned maintenance and preclinical-versus-human distinction; not automatically content-monitored.
• ClinicalTrials.gov NCT06842186: INLIGHT monotherapyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 24 February 2025 · Updated 2 June 2026Start 31 January 2025 (actual) · Primary completion 1 December 2027 (estimated) · Completion 1 December 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Novo Nordisk's sponsor-submitted NCT06577766 record studies subcutaneous single and multiple ascending doses of NNC0638-0355 in adults with overweight or obesity. It records an actual 3 September 2024 start, active-not-recruiting status and 63 actual participants; completion remains estimated for 11 October 2027.

• ClinicalTrials.gov NCT06577766: NNC0638-0355Trial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 29 August 2024 · Updated 30 September 2026Start 3 September 2024 (actual) · Primary completion 11 October 2027 (estimated) · Completion 11 October 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The investigator-submitted NCT07495904 record describes a 130-participant Greek study comparing standard Mediterranean-diet counselling with individualised higher-protein guidance during GLP-1 receptor-agonist treatment. It measures muscle mass through 24 weeks, with body composition, grip strength, sarcopenia risk and later weight maintenance among secondary outcomes.

• ClinicalTrials.gov NCT07495904: LEAN-PRO GLP-1Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 27 March 2026 · Updated 2 April 2026Start 30 March 2026 (estimated) · Primary completion 30 March 2028 (estimated) · Completion 30 January 2029 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 3 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Viking's sponsor-submitted NCT07846033 record studies single subcutaneous doses of VK3019 in adults with overweight or obesity. It records a recruiting Phase 1 study, an actual 6 July 2026 start and 56 estimated participants. Viking's 24 June announcement identifies VK3019 as an investigational dual amylin and calcitonin receptor agonist and describes the single-ascending-dose study.

• ClinicalTrials.gov NCT07846033: VK3019Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 29 September 2026 · Updated 29 September 2026Start 6 July 2026 (actual) · Primary completion 2 October 2026 (estimated) · Completion 1 November 2026 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Viking Therapeutics: Phase 1 VK3019 study initiationOriginal source — see findings and limitations · Published 24 June 2026 · Reviewed 3 October 2026 · Complete original sponsor announcement read for the investigational DACRA description and announced single-ascending-dose Phase 1 study; the later registry controls actual start and current recruitment status; not automatically content-monitored.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Antag Therapeutics' 28 July 2026 announcement identifies AT7687 as its peptide GIP-receptor antagonist and links it directly to NCT07724340. The sponsor-submitted registry uses the intervention code AT673 for the same 13-week Phase 2 study of two once-weekly subcutaneous doses or placebo alongside semaglutide in adults with type 2 diabetes and overweight or obesity. The registry records an actual 19 June 2026 start, active-not-recruiting status, eight US locations and 150 estimated participants.

• ClinicalTrials.gov NCT07724340: AT673 with semaglutideTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 24 July 2026 · Updated 29 September 2026Start 19 June 2026 (actual) · Primary completion 1 February 2027 (estimated) · Completion 1 March 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Antag Therapeutics: first participant dosed in AT7687 Phase 2a studyOriginal source — see findings and limitations · Published 28 July 2026 · Reviewed 6 October 2026 · Complete original sponsor announcement read for the AT7687 name, peptide GIP-receptor-antagonist description, first-participant statement, direct NCT07724340 link, 13-week combination design and planned 150 participants; not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

ZP6590 is an investigational long-acting GIP receptor agonist designed for co-formulation with other peptides. A sponsor-submitted record describes an 88-participant (estimated) first-in-human study of ZP6590 injections versus placebo, with an actual 9 July 2026 start. The record lists recruitment in Germany and no posted results.

• Zealand Pharma ZP6590 pipelineSponsor pipeline; preclinical aims and outdated trial-start narrative · Published/updated: Not stated by the source · Source review: 9 October 2026 · Source review required
• ClinicalTrials.gov NCT07721597: ZP6590Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 23 July 2026 · Updated 13 August 2026Start 9 July 2026 (actual) · Primary completion 6 September 2027 (estimated) · Completion 6 September 2027 (estimated)Medical evidence summary reviewed 3 October 2026 · Record status reviewed 10 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Zealand Pharma H1 2026: first-in-human ZP6590 trial initiatedOriginal source — see findings and limitations · Published 13 August 2026 · Reviewed 3 October 2026 · Complete original sponsor announcement read; initiation statement corroborates the registry. Not automatically content-monitored.
• CTIS 2026-525978-19-00: ZP6590-26033Original source — see findings and limitations · Published Not stated by the source · Reviewed 10 October 2026 · Official CTIS summary reviewed: matching protocol, ongoing/recruiting, Human Pharmacology Phase I and actual 9 July 2026 trial/recruitment start in Germany. EU estimated end 30 June 2027 is distinct from the ClinicalTrials.gov estimate. Publication date unknown. Not automatically content-monitored.
• Zealand Pharma H1 2026 interim report: ZP6590 initiationOriginal source — see findings and limitations · Published 13 August 2026 · Reviewed 10 October 2026 · Complete official PDF retrieved; dated company announcement and relevant pipeline discussion read. Supports sponsor-reported first-in-human initiation, not clinical outcomes. Unknown subsequent content-update date; not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

SRSD384 is an investigational subcutaneous GalNAc-conjugated siRNA targeting INHBE. Sirius reported on 1 July 2026 that the first participant had been dosed in a two-part Phase 1/2a study in Australia. Part A studies SRSD384 alone in people with overweight or obesity; Part B studies SRSD384 with tirzepatide in participants who also have type 2 diabetes. The sponsor-submitted registry record still says not yet recruiting, has an estimated June 2026 start and 78 estimated participants, and has no posted results.

• ClinicalTrials.gov NCT07557355: SRSD384Trial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 29 April 2026 · Updated 5 June 2026Start 1 June 2026 (estimated) · Primary completion 1 October 2027 (estimated) · Completion 1 October 2027 (estimated)Medical evidence summary reviewed 11 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Sirius Therapeutics: first participant dosed in SRSD384 Phase 1/2aOriginal source — see findings and limitations · Published 1 July 2026 · Reviewed 11 October 2026 · Complete original sponsor announcement read for reported first dosing, two-part design, Australian research and mechanism claims. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Fractyl describes RJVA-002 as an AAV-based, locally delivered gene-therapy candidate intended to make pancreatic beta cells express GIP and GLP-1 in response to nutrients. The sponsor reported body-weight changes after a single administration in a diet-induced-obesity mouse model; its August 2026 update still called RJVA-002 preclinical.

• Fractyl Health: preclinical RJVA-002 resultsPreclinical research — see limitations · Published 7 October 2025 · Reviewed 4 October 2026 · Complete sponsor announcement read for programme identity, mechanism, animal-model design and preclinical result. Not automatically content-monitored.
• Fractyl Health Q2 2026 business updatePreclinical research — see limitations · Published 10 August 2026 · Reviewed 4 October 2026 · Complete sponsor update read to verify that RJVA-002 remained preclinical and distinct from RJVA-001 and Revita. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Artelo describes ART27.13 as an oral, peripherally restricted cannabinoid receptor agonist and says it initiated a non-clinical study in models relevant to GLP-1-associated muscle preservation. The proposed obesity use remains exploratory and is distinct from the compound's human CAReS programme in cancer anorexia and cachexia.

• Artelo Biosciences: ART27.13 GLP-1 companion explorationOriginal source — see findings and limitations · Published 25 March 2026 · Reviewed 4 October 2026 · Complete sponsor announcement read for programme status, proposed use, non-clinical study initiation, patent filing and separation from cancer-cachexia evidence. Not automatically content-monitored.
• Artelo Biosciences ART27.13 pipeline pageOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 4 October 2026 · Full readable sponsor pipeline page reviewed for the distinct Phase 1/2 CAReS indication and interim evidence context. Publication and update dates were not displayed and remain unknown. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

RGT-075 is Regor's investigational once-daily oral small-molecule GLP-1 receptor agonist. Regor reported Phase 2a topline observations from a 73-participant, 12-week study. The sponsor-submitted registry also records the separate 267-participant COMO-1 Phase 2b study as completed on 6 November 2025; neither registry record has posted results.

• ClinicalTrials.gov NCT06277934: RGT001-075 Phase 2aTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 26 February 2024 · Updated 7 August 2025Start 8 March 2024 (actual) · Primary completion 13 August 2024 (actual) · Completion 13 August 2024 (actual)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06867718: COMO-1 Phase 2bTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 10 March 2025 · Updated 28 May 2026Start 24 January 2025 (actual) · Primary completion 6 November 2025 (actual) · Completion 6 November 2025 (actual)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Regor: Phase 2a topline announcement and COMO-1 initiationOriginal source — see findings and limitations · Published 10 January 2025 · Reviewed 4 October 2026 · Complete original sponsor announcement read for reported Phase 2a topline observations, planned Phase 2b design and the then-prospective end-2025 result timing. Not automatically content-monitored.
• Regor Therapeutics pipeline pageOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 4 October 2026 · Complete current sponsor page read for identity, oral GLP-1 mechanism and its undated Phase II-trials-in-progress label. Publication and update dates were not displayed. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

CX11/VCT220 is an investigational once-daily oral non-peptide small-molecule GLP-1 receptor agonist. A 250-participant Chinese Phase II study has a peer-reviewed publication, while the 840-participant Chinese Phase III and 250-participant US Phase II registry records are completed but have no posted results. A separate 160-participant hypertension study in people with obesity or overweight is active, not recruiting.

• ClinicalTrials.gov NCT06569355: VCT220 China Phase IITrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 26 August 2024 · Updated 1 July 2025Start 27 December 2023 (actual) · Primary completion 13 July 2024 (actual) · Completion 1 August 2024 (actual)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06939296: VCT220 China Phase IIITrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 22 April 2025 · Updated 16 September 2026Start 24 December 2024 (actual) · Primary completion 25 November 2025 (actual) · Completion 31 March 2026 (actual)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07011797: CX11 US Phase IITrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 10 June 2025 · Updated 28 May 2026Start 17 June 2025 (actual) · Primary completion 23 March 2026 (actual) · Completion 9 April 2026 (actual)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT07360275: VCT220 hypertension Phase IITrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 22 January 2026 · Updated 21 September 2026Start 1 March 2026 (actual) · Primary completion 30 October 2026 (estimated) · Completion 20 December 2026 (estimated)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Peer-reviewed VCT220 Chinese Phase II publicationPeer-reviewed Phase II publication · Published 14 August 2026 · Reviewed 4 October 2026 · Complete abstract and study metadata reviewed, including the 250-person randomized design, sponsor funding and employee conflicts. Not automatically content-monitored.
• Vincentage: VCT220 China Phase III topline announcementOriginal sponsor announcement · Published 18 May 2026 · Reviewed 4 October 2026 · Complete announcement reviewed for sponsor-reported Phase III topline observations and planned China NDA submission. Not automatically content-monitored.
• Corxel: CX11 US Phase II topline announcementOriginal sponsor announcement · Published 23 June 2026 · Reviewed 4 October 2026 · Complete announcement reviewed for sponsor-reported Phase II topline observations, the 246-person announcement count and planned global Phase III development. Not automatically content-monitored.
• Corxel: worldwide ex-Greater China rights to CX11/VCT220Original sponsor announcement · Published 23 December 2024 · Reviewed 4 October 2026 · Complete announcement reviewed for candidate identity and territorial development rights. Rights are not marketing authorisation or supply. Not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

BioAge discontinued dosing and enrolment in the STRIDES Phase 2 obesity study on 6 December 2024 after liver transaminitis without clinically significant symptoms was observed in 11 of 204 enrolled participants in azelaprag groups. The sponsor-submitted registry records the study as terminated with an actual 12 February 2025 completion, and BioAge's later annual filing says development of azelaprag was terminated in January 2025.

• BioAge Labs: STRIDES Phase 2 discontinuationOriginal sponsor discontinuation announcement · Published/updated: 6 December 2024 · Source review: 11 October 2026 · Source review required
• ClinicalTrials.gov NCT06515418: STRIDESTrial registry record · Last reviewed record: Terminated · No results posted at record-status review · First posted 23 July 2024 · Updated 13 March 2025Start 27 June 2024 (actual) · Primary completion 6 February 2025 (actual) · Completion 12 February 2025 (actual) · Stopping reason: Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.Medical evidence summary reviewed 11 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• BioAge Labs 2024 Form 10-KOriginal source — see findings and limitations · Published 20 March 2025 · Reviewed 11 October 2026 · Complete SEC filing section read for the later statement that azelaprag development was terminated in January 2025. Filing publication date was not independently verified and remains unknown. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Biohaven completed enrolment in a US Phase 2 dose-ranging monotherapy study of weekly and four-weekly taldefgrobep alfa in adults with overweight or obesity. The registry records an actual 24 November 2025 start, an estimated September 2026 completion and no posted results.

• Biohaven: Phase 2 taldefgrobep obesity study completes enrolmentOriginal source — see findings and limitations · Published 19 March 2026 · Reviewed 4 October 2026 · Complete sponsor announcement read for enrolment, study design, planned dose schedules and planned endpoints. Sponsor descriptions of potential benefit are not treated as results. Not automatically content-monitored.
• ClinicalTrials.gov NCT07281495: taldefgrobep alfa in adults with overweight and obesityTrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 15 December 2025 · Updated 20 March 2026Start 24 November 2025 (actual) · Primary completion 1 September 2026 (estimated) · Completion 1 September 2026 (estimated)Medical evidence summary reviewed 4 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Biohaven second-quarter 2026 business updateOriginal source — see findings and limitations · Published 10 August 2026 · Reviewed 4 October 2026 · Sponsor update read to confirm enrolment remained complete and that topline timing was still forward-looking. Not automatically content-monitored.

Evidence summary reviewed 4 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Rivus is developing RV-8451 as an oral non-peptide GLP-1 receptor agonist for obesity. The reviewed evidence is limited to diet-induced-obesity non-human-primate studies; the sponsor says IND-enabling work is under way and plans a US IND submission for Q1 2027.

• Rivus: preclinical RV-8451 data at ADA 2026Original source — see findings and limitations · Published 5 June 2026 · Reviewed 4 October 2026 · Complete sponsor announcement read for modality, preclinical species, study durations, reported endpoints and planned IND timing. Preclinical comparisons are not presented as human benefit or superiority. Not automatically content-monitored.
• Rivus oral-medicines pipelineOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 4 October 2026 · Full readable sponsor pipeline page reviewed to confirm RV-8451 remains in IND-enabling studies. Publication and update dates were not displayed and remain unknown. Not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted NCT07589686 record describes a Phase 2 dose-finding study of weekly petrelintide co-administered with weekly enicepatide in adults with obesity or overweight. The study remains not yet recruiting even though its estimated 30 September 2026 start date has passed; enrolment of 486 and the January 2028 completion remain estimates.

• ClinicalTrials.gov NCT07589686: ZYNERGYTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 15 May 2026 · Updated 9 September 2026Start 30 September 2026 (estimated) · Primary completion 12 November 2027 (estimated) · Completion 31 January 2028 (estimated)Medical evidence summary reviewed 11 October 2026 · Record status reviewed 11 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted NCT07767175 record describes a first-in-human study of subcutaneous NNC0721-8060 in adults with overweight or obesity. It is recruiting after an actual 12 August 2026 start and includes semaglutide and placebo arms.

• ClinicalTrials.gov NCT07767175: NNC0721-8060 first-in-human studyTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 17 August 2026 · Updated 4 September 2026Start 12 August 2026 (actual) · Primary completion 23 September 2027 (estimated) · Completion 23 September 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Gan & Lee describes GZC8072 as an investigational ultra-long-acting oral peptide GLP-1 receptor agonist designed for once-weekly administration. The sponsor-submitted NCT07784699 record studies a single oral dose in healthy adults and multiple oral doses in adults with overweight or obesity. It records recruiting Phase 1 research in China, an actual 2 September 2026 start and 126 estimated participants.

• Gan & Lee: GZC8072 obesity clinical-trial approvalOriginal Gan & Lee sponsor announcement; Chinese clinical-trial permission, not marketing authorisation · Published/updated: 7 September 2026 · Source review: 12 October 2026 · Source review required
• ClinicalTrials.gov NCT07784699: GZC8072Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 25 August 2026 · Updated 30 September 2026Start 2 September 2026 (actual) · Primary completion 18 August 2027 (estimated) · Completion 18 August 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Gan & Lee: first participant dosed in GZC8072 Phase 1Original source — see findings and limitations · Published 9 September 2026 · Reviewed 5 October 2026 · Complete sponsor-distributed announcement read for reported first dosing, intended weekly oral formulation and the earlier 112-participant plan. The later registry controls current status and estimated enrolment. Not automatically content-monitored.

Evidence summary reviewed 5 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Aardvark describes ARD-201 as a planned once-daily oral fixed-dose combination of ARD-101 and a DPP-4 inhibitor. Its August 2026 SEC filing says POWER began in December 2025 to study prevention of weight regain after more than 15% GLP-1-receptor-agonist-associated weight loss. STRENGTH was planned to study weight loss, including ARD-201 alone and with GLP-1 therapy. Both programmes were voluntarily paused on 27 February 2026.

• Aardvark Therapeutics second-quarter 2026 Form 10-QOriginal source — see findings and limitations · Published 11 August 2026 · Reviewed 5 October 2026 · Complete SEC filing read for POWER initiation, STRENGTH planning, the voluntary pause, the ARD-101 hold dependency and stated uncertainty. Not automatically content-monitored.
• Aardvark Therapeutics: voluntary pause of clinical programmesOriginal source — see findings and limitations · Published 27 February 2026 · Reviewed 5 October 2026 · Complete sponsor announcement read for the pause date, affected ARD-201 trials and the stated healthy-volunteer observations. Not automatically content-monitored.
• Aardvark Therapeutics ARD-201 programmesOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 5 October 2026 · Full sponsor programme page read for formulation, once-daily route and intended POWER/STRENGTH questions. The page displays 'Last Updated: October 2025' without an exact day and is treated as older context, not current trial status. Not automatically content-monitored.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis reported initiation of a US Phase I study of ASC36 oral tablets after FDA Investigational New Drug clearance. The study is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics after single and multiple ascending oral doses in 86 participants with obesity or overweight. This oral-tablet study is separate from ASC36 subcutaneous injection and ASC36_35FDC combination research.

• Ascletis: US Phase I study initiated for ASC36 oral tabletsOriginal Ascletis sponsor announcement; study initiation and plans, not trial results or marketing authorisation · Published/updated: 8 September 2026 · Source review: 12 October 2026 · Source review required
• Ascletis: US Phase I study initiated for ASC36 oral tabletsOriginal source — see findings and limitations · Published 8 September 2026 · Reviewed 12 October 2026 · Complete original sponsor announcement read for formulation, IND clearance, reported study initiation, planned population and endpoints, and animal-only findings. Automatic monitoring checks the bounded claim-bearing article text; it does not assess clinical outcomes.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Immunwork's sponsor-submitted NCT07857473 record describes TE-8105 as an injectable GLP-1 receptor agonist in a randomized, placebo-controlled Phase 2b study for adults with overweight or obesity. The record plans three subcutaneous dose-escalation cohorts, 25 weeks of treatment and up to 204 participants at two listed Australian locations.

• ClinicalTrials.gov NCT07857473: TE-8105 Phase 2bTrial registry record · Last reviewed record: Not yet recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 5 October 2026Start 1 October 2026 (estimated) · Primary completion 1 February 2028 (estimated) · Completion 1 February 2028 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 5 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

NCT07858864 observes 42 estimated adults in Turkey who start a GLP-1 or dual GLP-1/GIP medicine prescribed as routine obesity care. Over three months it records SARC-F screening, hand-grip strength, chair-stand and gait performance, bioelectrical-impedance body composition and routine laboratory results.

• ClinicalTrials.gov NCT07858864: GLP-1 use and sarcopenia observationTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 5 October 2026 · Updated 8 October 2026Start 30 May 2026 (actual) · Primary completion 30 November 2026 (estimated) · Completion 30 November 2026 (estimated)Medical evidence summary reviewed 5 October 2026 · Record status reviewed 8 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

710GO is an investigational oral peptide acting at melanocortin-3 and melanocortin-4 receptors. ANZCTR ACTRN12626000541303 (710GO-HV-01 Parts A/B), updated 2 July 2026, lists a randomized, blinded, placebo-controlled Australian Phase 1 study as recruiting, with actual first enrolment on 21 April 2026, a target of 120 and 11 enrolled at that update. The separately registered Part C food-effect crossover study ACTRN12626000540314, last updated 30 April 2026, still lists not yet recruiting and a target of 12.

• Kalohexis: 710GO first-in-human Phase 1 first dosingOriginal source — see findings and limitations · Published 28 May 2026 · Reviewed 5 October 2026 · Original sponsor-distributed announcement read in full. Not automatically content-monitored; direct command-line retrieval returned HTTP 403. No approved retrieval fingerprint is created.
• ANZCTR ACTRN12626000541303: 710GO-HV-01 dose escalationOriginal source — see findings and limitations · Published 30 April 2026 · Reviewed 10 October 2026 · Complete official registry record read: Parts A/B only, Phase 1, recruiting, actual first enrolment 21 April 2026, target 120, dated accrual 11, anticipated future dates and no posted study results. Not automatically content-monitored.
• ANZCTR ACTRN12626000540314: 710GO-HV-01 Part C food effectOriginal source — see findings and limitations · Published 30 April 2026 · Reviewed 10 October 2026 · Complete official registry record read: separate open-label randomized food-effect crossover Part C, target 12, not yet recruiting, anticipated dates with actual dates blank, no results documents. Not automatically content-monitored.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

GUB-UCN2 is an investigational subcutaneous urocortin-2 analogue and selective CRHR2 agonist. Gubra reported on 28 July 2026 that the first participant had completed the first visit in a three-part Phase 1/2a study. The sponsor-submitted registry records a recruiting study with an actual 27 July 2026 start, approximately 188 planned participants, and monotherapy and incretin-combination cohorts. Muscle volume and muscle function are planned study endpoints.

• ClinicalTrials.gov NCT07702890: GUB-UCN2 Phase 1/2Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 14 July 2026 · Updated 10 September 2026Start 27 July 2026 (actual) · Primary completion 1 December 2028 (estimated) · Completion 1 December 2028 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Gubra: GUB-UCN2 Phase 1/2a initiationOriginal sponsor trial-initiation announcement · Published 28 July 2026 · Reviewed 6 October 2026 · Complete sponsor announcement read for first visit, design and planned cohorts. Preclinical body-composition statements are not human results. Not automatically content-monitored.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

The sponsor-submitted NCT05199090 record and Novartis patient summary describe a 126-participant Phase 2 obesity study that started in February 2022 and ended early in May 2023. Novartis says the observed tolerability-to-benefit balance was not favourable at the studied doses and that it decided not to continue studying MBL949 in obesity.

• ClinicalTrials.gov NCT05199090: MBL949 Phase 2Original source — see findings and limitations · Published 20 January 2022 · Reviewed 6 October 2026 · Complete sponsor-submitted registry record read for terminated status, stopping reason, actual dates, actual enrolment and posted-results state. Not automatically content-monitored because interpreting posted outcomes needs a separate factual review.
• Novartis patient results summary: CMBL949A12201Sponsor patient results summary · Published Not stated by the source · Reviewed 6 October 2026 · Complete eight-page sponsor PDF read for study population, early termination and the decision not to continue obesity development. The document does not state a publication or update date; both remain unknown. Not automatically content-monitored.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Bivamelagon is an investigational once-daily oral MC4R agonist studied in acquired hypothalamic obesity, not general obesity. Rhythm's 9 July 2025 announcement reports sponsor topline results from a 28-person randomized placebo-controlled Phase 2 study. A separate sponsor-submitted long-term extension is enrolling by invitation, with an actual 10 November 2025 start, 25 estimated participants and estimated April 2028 completion.

• Rhythm: bivamelagon Phase 2 topline resultsOriginal sponsor announcement; topline results, not regulatory approval · Published/updated: 9 July 2025 · Source review: 12 October 2026 · Source review required
• ClinicalTrials.gov NCT07156578: bivamelagon long-term extensionTrial registry record · Last reviewed record: Enrolling by invitation · No results posted at record-status review · First posted 5 September 2025 · Updated 10 February 2026Start 10 November 2025 (actual) · Primary completion 15 April 2028 (estimated) · Completion 15 April 2028 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

RM-718 is an investigational once-weekly injectable MC4R agonist being studied in acquired hypothalamic obesity. Rhythm's 4 August 2026 announcement reports preliminary Phase 2 findings from an ongoing open-label study: 11 participants were enrolled and seven had reached 16 weeks for the reported mean BMI analysis.

• Rhythm: preliminary RM-718 Phase 2 dataOriginal sponsor announcement; preliminary results, not regulatory approval · Published/updated: 4 August 2026 · Source review: 12 October 2026 · Source review required

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Gilead's sponsor-submitted record describes recruiting Phase 1 research of oral GS-4571. The study uses single and multiple ascending doses across healthy participants, adults with obesity without diabetes and adults with type 2 diabetes who do not have obesity. It has an actual 28 August 2024 start, 134 estimated participants and estimated February 2027 completion.

• ClinicalTrials.gov NCT06562907: oral GS-4571 Phase 1Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 20 August 2024 · Updated 6 October 2026Start 28 August 2024 (actual) · Primary completion 1 February 2027 (estimated) · Completion 1 February 2027 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 6 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Mayo Clinic's investigator-submitted record describes a 24-week placebo-controlled pilot of tirzepatide in 40 estimated post-menopausal women with obesity. The study has an actual 8 April 2026 start and measures vasomotor-symptom frequency and severity alongside exploratory biological-age markers.

• ClinicalTrials.gov NCT07218445: tirzepatide menopause pilotTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 20 October 2025 · Updated 6 October 2026Start 8 April 2026 (actual) · Primary completion 18 September 2027 (estimated) · Completion 18 September 2027 (estimated)Medical evidence summary reviewed 6 October 2026 · Record status reviewed 6 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.

Evidence summary reviewed 9 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Lilly's sponsor-submitted records describe two completed open-label Phase 3b studies of ixekizumab with tirzepatide in adults with moderate-to-severe plaque psoriasis or psoriatic arthritis and obesity or overweight. A 31 August 2026 sponsor release reports prespecified exploratory week-52 findings. Two separate real-world Phase 4 studies have actual March 2025 starts: the psoriasis study is recruiting and the psoriatic-arthritis study is active, not recruiting. On 9 October 2026, Lilly reported a separate prespecified exploratory TOGETHER-PsO analysis of circulating proteins and blood gene expression, presented at Fall Clinical 2026. Broader biomarker changes with concomitant treatment were sponsor-reported as early as week 12 and at week 36.

• Lilly: TOGETHER-PsO and TOGETHER-PsA week-52 sponsor resultsOriginal sponsor announcement; exploratory open-label Phase 3b findings — see limitations · Published 31 August 2026 · Reviewed 9 October 2026 · Complete sponsor announcement read for design, sponsor-reported participant counts, week-52 exploratory findings, safety context and stated limitations. This page remains outside automatic content monitoring.
• ClinicalTrials.gov NCT06588283: TOGETHER-PsOTrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 19 September 2024 · Updated 17 June 2026Start 30 September 2024 (actual) · Primary completion 8 January 2026 (actual) · Completion 1 June 2026 (actual)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06588296: TOGETHER-PsATrial registry record · Last reviewed record: Completed · No results posted at record-status review · First posted 19 September 2024 · Updated 13 May 2026Start 24 September 2024 (actual) · Primary completion 18 November 2025 (actual) · Completion 23 April 2026 (actual)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06857942: TOGETHER AMPLIFY-PsOTrial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 5 March 2025 · Updated 4 September 2026Start 19 March 2025 (actual) · Primary completion 1 May 2028 (estimated) · Completion 1 May 2028 (estimated)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• ClinicalTrials.gov NCT06864026: TOGETHER AMPLIFY-PsATrial registry record · Last reviewed record: Active, not recruiting · No results posted at record-status review · First posted 7 March 2025 · Updated 21 September 2026Start 6 March 2025 (actual) · Primary completion 1 August 2027 (estimated) · Completion 1 August 2027 (estimated)Medical evidence summary reviewed 9 October 2026 · Record status reviewed 9 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.
• Lilly: TOGETHER-PsO exploratory biomarker findings — 9 October 2026Exploratory biomarker analysis; original sponsor announcement — see limitations · Published 9 October 2026 · Reviewed 9 October 2026 · Original announcement read through trial design, exploratory findings, US safety summaries and forward-looking limitations. Outside automatic content monitoring; no new fingerprint or green baseline.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Mwyngil's pipeline names MW-401 as a selective oral GPR75 antagonist in preclinical development. Its separate 25 June 2026 announcement reports diet-induced-obesity mouse findings for a GPR75 inverse-agonist programme and says candidate optimisation is continuing.

• Mwyngil pipeline: MW-401Preclinical research — see limitations · Published Not stated by the source · Reviewed 10 October 2026 · Official sponsor pipeline read in full for programme name, modality and preclinical stage; no verified publication or update date. Not automatically content-monitored.
• Mwyngil: GPR75 preclinical proof-of-concept announcementPreclinical research — see limitations · Published 25 June 2026 · Reviewed 10 October 2026 · Official dated sponsor announcement read in full; animal findings remain preclinical and are not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Palatin's 28 September 2026 business update describes non-lipidated PL1000 and lipidated PL2000 melanocortin-4-receptor peptide series in preclinical and IND-enabling work, with specialist development plans that include hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome.

• Palatin FY2026 results and business updatePreclinical research — see limitations · Published 28 September 2026 · Reviewed 10 October 2026 · Official dated sponsor release read in full for preclinical stage, specialist indications and explicitly planned development events; not automatically content-monitored.
• Palatin September 2026 corporate presentationOriginal source — see findings and limitations · Published 28 September 2026 · Reviewed 10 October 2026 · Official sponsor presentation read for programme identity and preclinical evidence only; animal data are not human outcomes. Not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis describes ASC39 as a once-daily oral small-molecule selective amylin receptor agonist. Its 3 August 2026 portfolio update reports only animal findings and listed a US IND filing for the third quarter of 2026; no accessible official source reviewed on 10 October confirmed that filing or a human study.

• Ascletis: oral GLP-1/GIP/amylin portfolio updateOriginal source — see findings and limitations · Published 3 August 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for programme composition, animal-only evidence and planned filing status. Not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis selected a once-daily oral fixed-dose combination of ASC30 and ASC39 for clinical development. The reviewed April and August 2026 sponsor announcements report formulation, pharmacokinetic and animal findings and planned a US IND filing in the third quarter of 2026; no accessible official source reviewed on 10 October confirmed that filing or first dosing.

• Ascletis: ASC30_39 FDC selected for clinical developmentOriginal source — see findings and limitations · Published 7 April 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for candidate selection, non-human evidence and planned filing. Not automatically content-monitored.
• Ascletis: oral GLP-1/GIP/amylin portfolio updateOriginal source — see findings and limitations · Published 3 August 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for current dated portfolio status. Not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis selected a once-daily oral fixed-dose combination of ASC30 and ASC48 for clinical development. The sponsor reports only non-human-primate weight findings and planned a US IND filing in the fourth quarter of 2026; the reviewed sources do not establish a completed filing, clearance or human study.

• Ascletis: ASC30_48 FDC selected for clinical developmentOriginal source — see findings and limitations · Published 15 July 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for candidate selection, animal-only evidence and planned filing. Not automatically content-monitored.
• Ascletis: oral GLP-1/GIP/amylin portfolio updateOriginal source — see findings and limitations · Published 3 August 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for current dated portfolio status. Not automatically content-monitored.

Evidence summary reviewed 10 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Ascletis describes a once-daily oral fixed-dose combination of ASC30, ASC48 and ASC39 targeting GLP-1, GIP and amylin receptors. Its 3 August 2026 announcement reports only non-human-primate findings and planned a US IND filing in the fourth quarter of 2026; no human trial or completed filing is established.

• Ascletis: oral GLP-1/GIP/amylin portfolio updateOriginal source — see findings and limitations · Published 3 August 2026 · Reviewed 10 October 2026 · Complete sponsor-distributed announcement read for programme composition, animal-only evidence and planned filing status. Not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

An investigational RNA-interference therapeutic targeting ACVR1C in adipose tissue. Alnylam's current trial page describes an enrolling 156-participant study of single and multiple ALN-2232 doses, including a separate part co-initiated with tirzepatide; the sponsor reported Phase 1 initiation on 30 April 2026.

• Alnylam ALN-2232-001 trial pageOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 11 October 2026 · Official sponsor trial page read for enrolling status, NCT07463846, 156 participants, interventions and 2 March 2026 to 2 March 2028 study dates; publication and update dates were not verified; not automatically content-monitored.
• Alnylam Q1 2026 resultsOriginal source — see findings and limitations · Published 30 April 2026 · Reviewed 11 October 2026 · Original sponsor release read for Phase 1 initiation, ACVR1C target, adipose-directed RNAi description and planned later data; not automatically content-monitored.
• Alnylam clinical development pipelineOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 11 October 2026 · Official pipeline read for current Phase 1 placement, ACVR1C target and obesity/weight-management indication; the page says updated July 2026 but does not state a day; not automatically content-monitored.

Evidence summary reviewed 11 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

A separate investigational RNA-interference therapeutic targeting inhibin E (INHBE). Alnylam's current trial page describes an enrolling, placebo-controlled, single-ascending-dose Phase 1 study of subcutaneous ALN-6222 in 88 adults with obesity; the sponsor reported trial initiation on 30 July 2026.

• Alnylam ALN-6222-001 trial pageOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 11 October 2026 · Official sponsor trial page read for enrolling status, NCT07624071, 88 participants, single-dose design and 4 June 2026 to 14 December 2027 study dates; publication and update dates were not verified; not automatically content-monitored.
• Alnylam Q2 2026 resultsOriginal source — see findings and limitations · Published 30 July 2026 · Reviewed 11 October 2026 · Original sponsor release read for Phase 1 initiation, INHBE target and adult-obesity scope; not automatically content-monitored.
• Alnylam clinical development pipelineOriginal source — see findings and limitations · Published Not stated by the source · Reviewed 11 October 2026 · Official pipeline read for current Phase 1 placement, INHBE target and obesity/weight-management indication; the page says updated July 2026 but does not state a day; not automatically content-monitored.

Evidence summary reviewed 12 October 2026 · Factual source review, not clinical approval

This evidence summary is due for factual review. A successful source check does not renew it.

Lilly's sponsor-submitted record describes recruiting Phase 1 single- and multiple-ascending-dose research of subcutaneous LY4329090 in otherwise healthy adults with obesity or overweight. It records an actual 22 September 2026 start, 184 estimated participants and estimated September 2027 completion.

• ClinicalTrials.gov NCT07808073: LY4329090 obesity or overweight Phase 1Trial registry record · Last reviewed record: Recruiting · No results posted at record-status review · First posted 8 September 2026 · Updated 8 October 2026Start 22 September 2026 (actual) · Primary completion 1 September 2027 (estimated) · Completion 1 September 2027 (estimated)Medical evidence summary reviewed 12 October 2026 · Record status reviewed 12 October 2026 · Source review required · These are the dated reviewed facts, not a newly assessed live record. Status checks do not assess clinical outcomes.